Proliposomes, methods of making, and methods of use thereof

The nicotinamide riboside proliposome composition addresses the instability and low bioavailability of existing formulations by enhancing NAD+ levels and treating age-related diseases through a controlled mixing process.

WO2026232189A1PCT designated stage Publication Date: 2026-11-12PHARMAKO BIOTECH PTY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/AU2026/050445
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing nicotinamide riboside formulations are unstable and have low bioavailability, making them unsuitable for effective oral supplementation to increase NAD+ levels, which are crucial for mitigating age-related diseases.

Method used

A nicotinamide riboside proliposome composition is developed, comprising specific percentages of nicotinamide riboside chloride, a lipid system, dispersant, and excipient, prepared through a controlled mixing process, which forms stable liposomes upon exposure to mucosal membranes, enhancing bioavailability.

Benefits of technology

The proliposome composition effectively increases NAD+ levels, mitigates age-related decreases, and treats associated diseases by providing enhanced stability and bioavailability of nicotinamide riboside.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000020_0001
    Figure IMGF000020_0001
  • Figure IMGF000026_0001_TABLE
    Figure IMGF000026_0001_TABLE
  • Figure IMGF000059_0001_TABLE
    Figure IMGF000059_0001_TABLE
Patent Text Reader

Abstract

Provided are proliposome compositions, method of preparation, and uses thereof in delivering active ingredients to a subject. The provided proliposome compositions comprise minimal ingredients and deliver active ingredients to a subject with high bioavailability. The method of preparing the proliposome compositions is an improved method with reduced production time, cost suitable to a wide variety of active ingredients, including temperature sensitive ingredients.
Need to check novelty before this filing date? Find Prior Art

Description

PROLIPOSOMES, METHODS OF MAKING, AND METHODS OF USE THEREOFENTITLEMENT

[0001] This application claims the benefit of and priority to Australian Provisional Patent Application No.2025901725 filed on 7 May 2025, which is incorporated herein by reference in its entirety.BACKGROUND

[0002] Nicotinamide adenine dinucleotide (NAD) is a coenzyme found in living cells, which through the cycling of its oxidized form (NAD+) to its reduced form (NADH), is critical to cellular energy metabolism as part of the citric acid cycle. The levels of NAD+ decrease with increasing aging, which is thought to contribute to age-associated diseases, such as diabetes, fatty liver, cardiovascular diseases, neurodegeneration, and muscular diseases. See, Iqbal and Nakagawa, Biochem BioPhys Res Comm (2024) 702:149590. Oral supplementation if NAD+ is not practical as it is not absorbed effectively through the gastrointestinal track. See Ito et al., Translational Medicine of Aging (2021) 5:43. Efforts to increase NAD+ have focused on administering compounds in the biological pathways to generate NAD+, including the NAD+ intermediates nicotinamide riboside and nicotinamide mononucleotide (NMN). While nicotinamide riboside supplementation is well tolerated, even in the chloride salt form (nicotinamide riboside chloride), it may be unstable in formulations and therefore not suitable for manufacturing, transport and storage conditions that are required to produce a supplement. See Bifa et al., Molecules (2023) 28(16): 6078. Increasing NAD+ through supplementation of NAD+ intermediates such as nicotinamide riboside has shown promise across a number of diseases and conditions. See Id.; Mehmel et al., Nutrients (2020) 12:1616.

[0003] Compliance with dietary supplements to increase NAD+, such as nicotinamide riboside supplementation, may benefit from formulations with extended shelf life and / or the ability to increase the bioavailability of NAD+ intermediates, such as nicotinamide riboside.

[0004] There is a need for a stable composition of nicotinamide riboside that may increase the bioavailability of the nicotinamide riboside.

[0005] It is an object of the present invention to substantially overcome, or at least ameliorate, one or more of the disadvantages of existing arrangements, or at least provide a useful alternative to existing arrangements.SUMMARY

[0006] The inventor surprisingly found that a nicotinamide riboside proliposome composition could be prepared with a minimum of ingredients and which boosts biologic NAD+ levels.

[0007] Provided is a method of(1) increasing NAD+ in a subject;(2) mitigating age-related decreases in NAD+ in a subject;(3) mitigating a disease, condition, and / or symptom associated with aging in a subject;(4) delaying the onset of a disease, condition, and / or symptom associated with aging in a subject;(5) treating a disease, condition, and / or symptom associated with aging in a subject;(6) dietary management of a disease, condition, and / or symptom associated with aging in a subject; comprising administering to the subject a nicotinamide riboside proliposome composition,wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.

[0008] Provided is a method of preparing a proliposome composition, comprising(a) preparing a first mixture of an organic solvent and a lipid system as herein described;(b) spraying the first mixture onto an active ingredient to form a second mixture, wherein the spraying is airless spraying;(c) adding to the second mixture a dispersant to form a third mixture; and(d) adding to the third mixture an excipient to form a final mixture.

[0009] Provided is a method of preparing a proliposome composition, wherein the method comprises:(a) preparing a first mixture of an organic solvent and a lipid system as herein described;(a’) adding an active ingredient into a high shear mixer;(b) spraying the first mixture onto the active ingredient to form a second mixture, wherein the spraying is airless spraying;(b’) mixing the second mixture in the high shear mixer;(c) adding to the second mixture a dispersant to form a third mixture;(c’) mixing the third mixture in the high shear mixer;(d) adding to the third mixture an excipient to form a final mixture; and(d’) mixing the final mixture in the high shear mixer;wherein(i) the method is carried out at about 20°C to about 25°C; and(ii) the mixing in each of (b’), (c’), and (d’) is no more than 10 minutes.

[0010] Provided is the proliposome composition obtained by the method of paragraph

[0008] or paragraph

[0009] , wherein the proliposome composition comprises(a) about 40% to about 70%, about 47% to about 64%, or about 52% to about 58%, of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.3% to about 6.7%, about 3.8% to about 6.2%, or about 4.3% to about 5.6%, of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45%, about 30% to about 41 %, or about 34% to about 37%, dispersant by weight based on the total weight of the composition;(d) about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition; and(e) no more than about 2%, about 0.5% to about 2%, no more than about 1.5%, or about 0.5% to about 1.5%, organic solvent based on the total weight of the composition.

[0011] Provided is a proliposome composition, wherein the proliposome composition comprises(a) about 40% to about 70%, about 47% to about 64%, or about 52% to about 58%, of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.3% to about 6.7%, about 3.8% to about 6.2%, or about 4.3% to about 5.6%, of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45%, about 30% to about 41 %, or about 34% to about 37%, dispersant by weight based on the total weight of the composition;(d) about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition; and(e) no more than about 2%, about 0.5% to about 2%, no more than about 1.5%, or about 0.5% to about 1.5%, organic solvent based on the total weight of the composition.

[0012] Provided is a proliposome composition, wherein the proliposome composition comprises(a) about 52% to about 58% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 4.3% to about 5.6% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 70% to about 80% phospholipid by weight based on the total weight of the lipid system;(c) about 34% to about 37%, dispersant by weight based on the total weight of the composition, wherein the dispersant is maltodextrin;(d) about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition, wherein the excipient is colloidal silica (anhydrous); and(e) about 0.5% to about 1.5%, organic solvent based on the total weight of the composition, wherein the organic solvent is ethanol;wherein(i) the phospholipid comprises at least about 90% phosphatidylcholine (PC) by weight based on the total weight of the phospholipid; about 3.8% to about 4.2% lysophosphatidylcholine (LPC) by weight based on the total weight of the phospholipid; and about 0.60% to about 0.70% phosphotidylethanolamine (PE) by weight based on the total weight of the phospholipid;(ii) the composition is the lipid system is substantially free of phosphatidic acid (PA) and / or phosphatidylinositol (PI); and(iii) wherein the composition has a mean particle size of no more than about 300 pm.BRIEF DESCRIPTION OF THE DRAWINGS

[0013] In the following detailed portion of the description, the teachings of the application will be explained in more detail with reference to the examples as shown in the drawings, in which:

[0014] FIG. 1 shows the NAD+ content in mouse plasma in the experiment described in Example s. Two-way ANOVA was used to analyze the differences between the experimental group and the control group, * represents P<0.05, ** represents P<0.01 , *** represents P<0.001 , **** represents P<0.0001. For each of day 8 (left) and day 15 (right), from left to right are CON, NR, NMN, LNR, and HNR.

[0015] FIG. 2 shows the NAD+ content in mouse liver in the experiment described in Example 3. Two-way ANOVA was used to analyze the differences between the experimental group and the control group, * represents P<0.05, ** represents P<0.01 , *** represents P<0.001 , **** represents P<0.0001. For each of day 8 (left) and day 15 (right), from left to right are CON, NR, NMN, LNR, and HNR.

[0016] FIG. 3 shows the stability investigation of the nicotinamide riboside proliposome composition at 25°C and 60% relative humidity. The nicotinamide riboside chloride (NR) content versions time in months. The upper horizontal line is the nicotinamide riboside chloride (NR) content (Upper Limit - 600 mg / g). The lower horizontal line is the nicotinamide riboside chloride (NR) content (Upper Limit - 450 mg / g). The measured nicotinamide riboside chloride (NR) content is plotted. The dotted line is the liner extrapolation. See Example 4.DETAILED DESCRIPTION

[0017] Certain terms, whether used alone or as part of a phrase or another term are defined below.

[0018] The articles “a” and “an” refer to one or to more than one of the grammatical object of the article.

[0019] The words “comprise,” “comprises” and “comprising” are to be interpreted inclusively rather than exclusively. Likewise, the terms “include,” “including” and “or” should all be construed to be inclusive, unless such a construction is clearly prohibited from the context. Nevertheless, the compositions and methods disclosed herein may lack any element that is not specifically disclosed herein. Thus, a disclosure using the term “comprising” includes a disclosure of “consisting essentially of’ and “consisting of’ the components or steps identified. In the context of the proliposome composition, including a nicotinamide riboside proliposome composition, the composition may be described as “consisting essentially of’, which is understood to mean that other ingredients may be included that do not materially alter the liposome forming activity of the composition and / or the mean particle size of the composition and / or the liposomal particle size (Z-average (d.nm)) for the composition when 100 mg of composition is mixed with 100 ml water.

[0020] The term “and / or” used in the context of “X and / or Y” should be interpreted as “X,” or “Y,” or “X and Y.” Similarly, “at least one of X or Y” should be interpreted as “X,” or “Y,” or “X and Y.”

[0021] Where used herein, the terms “example” and “such as,” particularly when followed by a listing of terms, are merely exemplary and illustrative and should not be deemed to be exclusive or comprehensive.

[0022] Percentages expressed herein are weight percentages unless indicated otherwise. Weight percentage may be expressed as “X% [component] by weight based on the total amount of the composition” or “X% by weight of [component] based on the total amount of the composition”, which are understood to be interchangeable.

[0023] As used herein, a disease or condition “associated with” or “linked with” another disease or condition, means the diseases or conditions occur concurrently, caused by the same underlying disease or condition, and / or caused by the other identified disease or condition. For example, the disease, condition, and / or symptom may be associated with aging in a subject, and may be linked to decreased NAD+. The disease, condition and / or symptom may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0024] Numerical values relating to measurements are subject to measurement errors that place limits on their accuracy. For this reason, the term “about’ may explicitly or implicitly modify all numerical values provided herein, unless otherwise indicated. The term “about’ generally indicates a possible variation of a numerical value. The possible variation (±) may be no more than 10%, 5%, or 1 % of the numerical value. The last decimal place of a numerical value provided herein may indicate its degree of accuracy. Where no other error margins are given, the maximum margin may be ascertained by applying the rounding-off convention to the last decimal place or last significant digit when a decimal is not present in the given numerical value. All numerical ranges herein should be understood to include all integers, whole or fractions, within the range. Moreover, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range, including the endpoints. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 1 to 10, 1 to 8, from 3 to 7, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.

[0025] As used herein, the term “prevention” or “preventing” refers to reduction of risk, incidence, frequency and / or severity of a condition or disease.

[0026] As used herein, the term “treatment’, “treating”, or “treat’ refer to an approach for obtaining beneficial or desired results including but not limited to a therapeutic benefit and / or a prophylactic benefit. By therapeutic benefit is meant any therapeutically relevant improvement in or effect on one or more diseases, conditions, or symptoms under treatment. For prophylactic benefit, the compositions may be administered to a subject at risk of developing a particular disease, condition, or symptom, or to a subject reporting one or more of the physiological symptoms of a disease, even though the disease, condition, or symptom may not have yet been manifested. As used herein "treating" includes ameliorating, curing, preventing a disease or condition from becoming worse, slowing the rate of progression, or preventing the disease or condition from re-occurring (preventing a relapse). The term does not necessarily imply that a subject is treated until total recovery. For example, the disease, condition, and / or symptom may be associated with aging in a subject, and may be linked to decreased NAD+. The disease, condition and / or symptom may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0027] As used herein, the term “mitigate” or “mitigating” refers to reduction or halting of progression of a condition or disease.

[0028] As used herein, the term “therapeutically effective amount’ refers to an amount that results in a therapeutic benefit and / or prophylactic amount. The term includes an amount that is ameliorating, curing, preventing a disease or condition from becoming worse, slowing the rate of progression, preventing the disease or condition from re-occurring (preventing a relapse), or reducing incidence of one or more symptoms of a disease, disorder, or condition. For example, the disease, condition, and / or symptom may be associated with aging in a subject, and may be linked to decreased NAD+. The disease, condition and / or symptom may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0029] As used herein, the terms “subject,” “individual,” and “patient’ are used interchangeably herein to refer to a vertebrate, a mammal, or a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets, including but not limited to cats, dogs, and rabbits. The subject may be a human.

[0030] As used herein, the term “in need of treatment’ refers to a judgment made by a caregiver (e g. physician, nurse, nurse practitioner, or individual in the case of humans; veterinarian in the case of animals, including nonhuman animals) that a subject requires or will benefit from treatment. This judgment may be made based on a variety of factors that are in the realm of a caregiver’s experience, but that include the knowledge that the subject is ill, or will be ill, as the result of a condition that is treatable by the nicotinamide riboside proliposome described herein.

[0031] The term “manage,” “managing,” and “management’ as used herein, including in the context of “dietary management’, refers to the prevention or reduction in severity or frequency of a disease, condition and / or symptom, including ameliorating one or more existing symptoms of a disease or condition, preventing one or more existing symptoms of disease or condition, preventing one or more underlying causes of a disease or condition, ameliorating one or more underlying cause of a disease or condition, reducing the prevalence of one or more symptoms of a disease or condition, and / or reducing the occurrence of one or more symptoms of a disease or condition. It will be understood to include stabilizing a disease or condition and preventing progression of a disease or condition. In the context of the products disclosed herein it understood that a compositions or products can be used in the dietary management of a disease, condition and / or symptom associated with aging, wherein the subject may benefit from an increase in NAD+ and wherein an increase in NAD+ cannot be achieved without supplementation of a diet with nicotinamide riboside. The nicotinamide riboside proliposome compositions may be in the form of a supplement and / or a product for dietary management in a subject that may be in need of NAD+ and / or of a disease, condition and / or symptom associated with aging.

[0032] As used herein, the term “substantially free of [component]” with respect to a proliposome composition means that only trace amounts of a particular component may be found in the composition and / or ingredient. “Substantially free of [component]” may mean no more than 0.1% of a particular component by weight based on the total weight of the composition, no more than 0.01% of a particular component by weight based on the total weight of the composition, or no more than 0.001 % of a particular component by weight based on the total weight of the composition. For example, a proliposome composition, including for example a nicotinamide ribosideproliposome composition, may be substantially free of phosphatidic acid. A proliposome composition, including for example a nicotinamide riboside proliposome composition, may comprise no more than 0.1% of phosphatidic acid by weight based on the total weight of the composition, no more than 0.01% phosphatidic acid by weight based on the total weight of the composition, or no more than 0.001% of phosphatidic acid by weight based on the total weight of the composition.

[0033] By the term “free of added [ingredient]” (e.g.) it is understood throughout this specification and the appended claims that the proliposome composition, including the nicotinamide riboside proliposome composition, is prepared without the addition of an amount of that ingredient. For the avoidance of doubt a proliposome composition that is referred to as “free of added [ingredient]” will be understood to be prepared without the addition of that ingredient and, thereby, the final proliposome composition does not include that ingredient. For example, “free of added cholesterol” refers to a proliposome composition, including a nicotinamide riboside proliposome composition, to which cholesterol is not added. For example, “free of added synthetic non-ionic surfactant’, refers to a proliposome composition, including a nicotinamide riboside proliposome composition, to which a synthetic non-ionic surfactant is not added. Exemplary synthetic non-ionic surfactants include, but are not limited to, polysorbates (e.g. polysorbate 80, polysorbate 20) and poloxamers (e.g. poloxamer 188). For example, “free of added polyethylene glycol (PEG)”, refers to a proliposome composition, including a nicotinamide riboside proliposome composition, to which PEG is not added.

[0034] PROLIPOSOME COMPOSITION

[0035] The term “proliposome,” which may be used interchangeably with “proliposome composition”, as used herein refers to a powder composition that upon exposure to suitable conditions forms a liposome. Exemplary suitable conditions include exposure to mucosal membranes or exposure to an aqueous medium. Exemplary mucosal membranes include the respiratory tract (e.g. nose, mouth, trachea, and / or lungs) and the digestive tract (mouth, esophagus, stomach, and / or intestine). Exemplary aqueous medium includes water and exemplary suitable liquids include, but are not limited to water and buffer solutions. The proliposome composition may form liposome upon exposure to the mucosal membranes of the nasal passageway. The proliposome composition may form liposome upon exposure to the lung. The proliposome composition may form liposome upon exposure to the mouth. The proliposome composition may form liposomes upon exposure to the digestive tract. The proliposome composition may form liposomes upon exposure to the stomach.

[0036] A proliposome composition comprises(a) about 40% to about 70% of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.

[0037] The proliposome composition may further comprise no more than about 2% organic solvent by weight based on the total weight of the composition.

[0038] A proliposome composition consists essentially of(a) about 40% to about 70% of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition;(d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition; and (e) no more than about 2% organic solvent by weight based on the total weight of the composition.

[0039] The one or more active ingredients may be a one or more hydrophilic active ingredients and / or one or more lipophilic active ingredients. Upon exposer to suitable conditions, the proliposome composition forms a liposome where when the active ingredient is a hydrophilic active ingredient, the liposome encapsulates the hydrophilic active ingredient in the liposome core. Upon exposer to suitable conditions, the proliposome composition forms a liposome where when the active ingredient is a lipophilic active ingredient, the liposome encapsulates the lipophilic active ingredient in the bilayer membrane.

[0040] When the proliposome composition comprises more than one active ingredient, the weight percent refers to the combined weight percent of all active ingredients.

[0041] A proliposome composition comprises(a) about 40% to about 70%, about 47% to about 64%, or about 52% to about 58%, of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.3% to about 6.7%, about 3.8% to about 6.2%, or about 4.3% to about 5.6%, of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45%, about 30% to about 41 %, or about 34% to about 37%, dispersant by weight based on the total weight of the composition; and(d) about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition.

[0042] The proliposome composition may further comprise no more than about 2%, about 0.5% to about 2%, no more than about 1.5%, or about 0.5% to about 1.5%, organic solvent by weight based on the total weight of the composition.

[0043] A proliposome composition consists essentially of(a) about 40% to about 70%, about 47% to about 64%, or about 52% to about 58%, of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.3% to about 6.7%, about 3.8% to about 6.2%, or about 4.3% to about 5.6%, of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45%, about 30% to about 41 %, or about 34% to about 37%, dispersant by weight based on the total weight of the composition;(d) about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition; and(e) no more than about 2%, about 0.5% to about 2%, no more than about 1.5%, or about 0.5% to about 1.5%, organic solvent by weight based on the total weight of the composition.

[0044] The proliposome composition comprises a lipid system, wherein the lipid system may comprise about 65% to about 85% or about 70% to about 80% phospholipid by weight based on the total weight of the lipid system.

[0045] The phospholipid comprised in the lipid system of the proliposome composition may comprise:(a) at least about 70%, at least about 80%, or at least about 90%, phosphatidylcholine (PC) by weight based on the total weight of the phospholipid;(b) about 3.0% to about 5.0%, about 3.4% to about 4.6%, or about 3.8% to about 4.2%, lysophosphatidy Icholine (LPC) by weight based on the total weight of the phospholipid; and(c) about 0.5% to about 0.8%, about 0.55% to about 0.75%, or about 0.6% to about 0.7%, phosphotidylethanolamine (PE) by weight based on the total weight of the phospholipid.

[0046] The phospholipid comprised in the lipid system of the proliposome composition may be substantially free of phosphatidic acid (PA) and / or phosphatidylinositol (PI). The lipid system of the proliposome composition may be substantially free of PA and / or PI. The lipid system of the proliposome composition may comprise no more than 0.1% PA by weight based on the total weight of lipid system and / or no more than 0.1% PI by weight based on the total weight of the lipid system. The lipid system of the proliposome composition may comprise no more than 0.01 % PA by weight based on the total weight of lipid system and / or no more than 0.01 % PI by weight based on the total weight of lipid system. The phospholipid comprised in the lipid system of the proliposome composition may comprise no more than 0.001% PA by weight based on the total weight of lipid system and / or no more than 0.001% PI by weight based on the total weight of lipid system.

[0047] A nicotinamide riboside proliposome composition comprises(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.

[0048] The nicotinamide riboside proliposome composition may further comprise no more than about 2% organic solvent by weight based on the total weight of the composition.

[0049] A nicotinamide riboside proliposome composition consists essentially of(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition;(d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition; and (e) no more than about 2% organic solvent by weight based on the total weight of the composition.

[0050] A nicotinamide riboside proliposome composition comprises(a) about 40% to about 70%, about 47% to about 64%, or about 52% to about 58%, nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7%, about 3.8% to about 6.2%, or about 4.3% to about 5.6%, of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45%, about 30% to about 41 %, or about 34% to about 37%, dispersant by weight based on the total weight of the composition; and(d) about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition.

[0051] The nicotinamide riboside proliposome composition may further comprise no more than about 2%, about 0.5% to about 2%, no more than about 1.5%, or about 0.5% to about 1.5%, organic solvent by weight based on the total weight of the composition.

[0052] A nicotinamide riboside proliposome composition consists essentially of(a) about 40% to about 70%, about 47% to about 64%, or about 52% to about 58%, nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7%, about 3.8% to about 6.2%, or about 4.3% to about 5.6%, of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45%, about 30% to about 41 %, or about 34% to about 37%, dispersant by weight based on the total weight of the composition;(d) about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition; and(e) no more than about 2%, about 0.5% to about 2%, no more than about 1.5%, or about 0.5% to about 1.5%, organic solvent by weight based on the total weight of the composition.

[0053] The nicotinamide riboside proliposome composition comprises a lipid system, wherein the lipid system may comprise about 65% to about 85% or about 70% to about 80% phospholipid by weight based on the total weight of the lipid system.

[0054] The phospholipid comprised in the lipid system of the nicotinamide riboside proliposome composition may comprise:(a) at least about 70%, at least about 80%, or at least about 90%, PC by weight based on the total weight of the phospholipid;(b) about 3.0% to about 5.0%, about3.4% to about 4.6%, about 3.8% to about 4.2%, LPC by weight based on the total weight of the phospholipid; and(c) about 0.5% to about 0.8%, about 0.55% to about 0.75%, about 0.6% to about 0.7%, PE by weight based on the total weight of the phospholipid.

[0055] The phospholipid comprised in the lipid system of the nicotinamide riboside proliposome composition may be substantially free of PA and / or PI. The lipid system may be substantially free of PA and / or PI. The lipid system of the nicotinamide riboside proliposome composition may comprise no more than 0.1% PA by weight based on the total weight of lipid system and / or no more than 0.1 % PI by weight based on the total weight of the lipid system. The lipid system of the nicotinamide riboside proliposome composition may comprise no more than 0.01 % PA by weight based on the total weight of the lipid system and / or no more than 0.01 % PI by weight based on the total weight of the lipid system phospholipid. The lipid system of the nicotinamide riboside proliposome composition may comprise no more than 0.001 % PA by weight based on the total weight of the lipid system and / or no more than 0.001 % PI by weight based on the total weight of the lipid system.

[0056] The nicotinamide riboside proliposome composition may be free of added cholesterol, free of added synthetic non-ionic surfactant, and / or free of added polyethylene glycol (PEG). The nicotinamide riboside proliposome composition may be free of added cholesterol, free of added synthetic non-ionic surfactant, and free of added polyethylene glycol (PEG).

[0057] PARTICLE SIZE OF A PROLIPOSOME COMPOSITION

[0058] The particle size of the proliposome composition, which is a powder, may be determined. A proliposome composition may have a mean particle size of no more about 400 pm, no more than about 350 pm, or no more than about 300 pm. A nicotinamide riboside proliposome composition may have a mean particle size of no more about 400 pm, no more than about 350 pm, or no more than about 300 pm.

[0059] A proliposome composition may have a mean particle size of no more no more than about 300 pm, wherein the Dw may be less than about 100 pm, the D50 may be less than about 200 pm, and the D90 may be less than about 400 pm. A nicotinamide riboside proliposome composition may have a mean particle size of no more no more than about 300 pm, wherein the Dw may be less than about 100 pm, the D50 may be less than about 200 pm, and the D90 may be less than about 400 pm.

[0060] The mean particle size of the proliposome may be determined by methods known in the art. An exemplary method includes laser diffraction. For example, particle size of the proliposome composition in the drystate (as a powder) by an Anton Paar Particle Size Analyzer L / D 1190, or its equivalent. Prior to measurement the proliposome composition may be sieved to break up agglomerates.

[0061] Z-AVERAGE (d.nm) OF A LIPOSOME (LIPOSOMAL PARTICLE SIZE (Z-averaqe (d.nm))

[0062] When 100 mg of a proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) of less than about 400 nm, less than about 350 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, or less than about 50 nm. The particle size of the resulting liposome is referred to herein as the “liposomal particle size (Z-average (d.nm))”. When 100 mg of a nicotinamide riboside proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) of less than about 400 nm, less than about 350 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, or less than about 50 nm. The 100 ml of water may be measured by weighing 100 g of water.

[0063] When 100 mg of a proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) of less than about 300 nm. When 100 mg of a nicotinamide riboside proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) of less than about 300 nm.

[0064] When 100 mg of a proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) of less than about 50 nm. When 100 mg of a nicotinamide riboside proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) of less than about 50 nm.

[0065] The Z-average (d.nm) provides a measure the average size of a particle distribution. As used herein “Z-average (d.nm)” refers to the intensity-weighted mean particle diameter derived from the cumulants analysis. Methods of measuring the Z-average (d.nm) are known to the person skilled in the art, e.g. ISO 22412:2017. The Z-average (d.nm) may be measured by Dynamic Light Scattering. The Z-average (d.nm) may be measured by Dynamic Light Scattering as described in ISO 22412:2017. The Z-average (d.nm) size may be measured with Multi-Angle Dynamic Light Scattering with, e.g. using the Malvern Zetasizer Ultra or an equivalent.

[0066] LIPID SYSTEM

[0067] A proliposome composition, including a nicotinamide riboside proliposome composition, comprises a lipid system, wherein the composition comprises about 3.3% to about 6.7%, about 3.8% to about 6.2%, or about 4.3% to about 5.6%, of a lipid system by weight based on the total weight of the composition, and wherein the lipid system comprises about 50% to about 95%, about 65% to about 85%, or about 70% to about 80%, phospholipid by weight based on the total weight of the lipid system.

[0068] A proliposome composition, including a nicotinamide riboside proliposome composition, comprises a lipid system, wherein the composition comprises about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, and wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system. A proliposome composition, including a nicotinamide riboside proliposome composition, comprises a lipid system, wherein the composition comprises about 3.8% toabout 6.2% of a lipid system by weight based on the total weight of the composition, and wherein the lipid system comprises about 65% to about 85% phospholipid by weight based on the total weight of the lipid system. A proliposome composition, including a nicotinamide riboside proliposome composition, comprises a lipid system, wherein the composition comprises about 4.3% to about 5.6% of a lipid system by weight based on the total weight of the composition, and wherein the lipid system comprises about 70% to about 80%, phospholipid by weight based on the total weight of the lipid system.

[0069] The phospholipid comprised in the lipid system of a proliposome composition, including a nicotinamide riboside proliposome composition, may comprise:(a) at least about 70%, at least about 80%, or at least about 90%, PC by weight based on the total weight of the phospholipid;(b) about 3.0% to about 5.0%, about 3.4% to about 4.6%, about 3.8% to about 4.2%, LPC by weight based on the total weight of the phospholipid; and(c) about 0.5% to about 0.8%, about 0.55% to about 0.75%, about 0.6% to about 0.7%, PE by weight based on the total weight of the phospholipid.

[0070] The phospholipid comprised in the lipid system of a proliposome composition, including a nicotinamide riboside proliposome composition, may comprise:(a) at least about 70% to about 97% PC by weight based on the total weight of the phospholipid;(b) about 3.0% to about 5.0% LPC by weight based on the total weight of the phospholipid; and(c) about 0.5% to about 0.8% PE by weight based on the total weight of the phospholipid.

[0071] The phospholipid comprised in the lipid system of a proliposome composition, including a nicotinamide riboside proliposome composition, may comprise:(a) at least about 80 to about 97% PC by weight based on the total weight of the phospholipid;(b) about 3.4% to about 4.6% LPC by weight based on the total weight of the phospholipid; and(c) about 0.55% to about 0.75% PE by weight based on the total weight of the phospholipid.

[0072] The phospholipid comprised in the lipid system of a proliposome composition, including a nicotinamide riboside proliposome composition, may comprise:(a) at least about 90% to about 97% PC by weight based on the total weight of the phospholipid;(b) about 3.8% to about 4.2% LPC by weight based on the total weight of the phospholipid; and(c) about 0.6% to about 0.7% PE by weight based on the total weight of the phospholipid.

[0073] The phospholipid comprised in the lipid system of a proliposome composition, including a nicotinamide riboside proliposome composition, may be substantially free of PA and / or PI. The lipid system of a proliposome composition, including a nicotinamide riboside proliposome composition, may be substantially free of PA and / or PI. The lipid system of a proliposome composition, including a nicotinamide riboside proliposome composition, may comprise no more than 0.1 % PA by weight based on the total weight of the lipid system and / or no more than 0.1 % PI by weight based on the total weight of the lipid system. The lipid system of a proliposome composition, including a nicotinamide riboside proliposome composition, may comprise no more than 0.01% PA by weightbased on the total weight of the lipid system and / or no more than 0.01% PI by weight based on the total weight of the lipid system. The lipid system of a proliposome composition, including a nicotinamide riboside proliposome composition, may comprise no more than 0.001% PA by weight based on the total weight of the lipid system and / or no more than 0.001 % PI by weight based on the total weight of the lipid system.

[0074] The lipid system may comprise lecithin. The lipid system may consist of lecithin. It is understood that lecithin comprises a mixture of phospholipid, glycolipid, carbohydrate, neutral lipid, free fatty acid, and moisture.

[0075] The lipid system may comprise a deoiled lecithin. The lipid system may consist essentially of a deoiled lecithin. It is understood that deoiled lecithin is a lecithin that has been processes to remove neutral lipid and thereby is a lecithin with an increased percentage of PC. Deoiled lecithin may be treated to further enrich the percentage of PC by removing other components of the lecithin such as any one of the glycolipid, carbohydrate, free fatty acid and / or remaining neutral lipid. The deoiled lecithin may be a vegetable deoiled lecithin. Exemplary vegetable deoiled lecithin include sunflower deoiled lecithin, soy deoiled lecithin, canola deoiled lecithin, and rapeseed deoiled lecithin. The lipid system may comprise a deoiled lecithin, wherein the deoiled lecithin may be one or more of sunflower deoiled lecithin, canola deoiled lecithin, rapeseed deoiled lecithin, and / or soy deoiled lecithin.

[0076] The lipid system comprised in a proliposome composition, including a nicotinamide riboside proliposome composition, may comprise sunflower deoiled lecithin. The lipid system comprised in a proliposome composition, including a nicotinamide riboside proliposome composition, may consist essentially of sunflower deoiled lecithin. The lipid system comprised in a proliposome composition, including a nicotinamide riboside proliposome composition, may consist of sunflower deoiled lecithin.

[0077] The lipid system may comprise a deoiled lecithin enriched in PC. The lipid system may consist essentially of a deoiled lecithin enriched in PC. The deoiled lecithin may be a vegetable deoiled lecithin enriched in PC. Exemplary vegetable deoiled lecithin enriched in PC include sunflower deoiled lecithin enriched in PC, soy deoiled lecithin enriched in PC, canola deoiled lecithin enriched in PC, and rapeseed deoiled lecithin enriched in PC. The lipid system may comprise a deoiled lecithin enriched in PC, wherein the deoiled lecithin enriched in PC may be one or more of sunflower deoiled lecithin enriched in PC, canola deoiled lecithin enriched in PC, rapeseed deoiled lecithin enriched in PC, and / or soy deoiled lecithin enriched in PC.

[0078] The lipid system comprised in a proliposome composition, including a nicotinamide riboside proliposome composition may comprise lecithin, wherein the lecithin may comprise from at least about 80% lipid to at least about 95% lipid by weight based on based on the total amount of the lecithin. The lipid system comprised in a proliposome composition, including a nicotinamide riboside proliposome composition may comprise lecithin, wherein the lecithin may comprise at least about 80% lipid, at least about 85% lipid, at least about 90% lipid, or at least about 95% lipid by weight based on the total amount of the lecithin.

[0079] The lipid system may comprise a lecithin, wherein the lecithin comprises (a) about 50% to about 90% PC by weight based on the total weight of the lecithin; (b) about 2.3% to about 4% LPC by weight based on the total weight of the lecithin; and (c) about 0.3% to about 0.7% PE by weight based on the total weight of the lecithin.The lipid system may comprise a lecithin, wherein the lecithin comprises (a) about 62% to about 85% PC by weight based on the total weight of the lecithin; (b) about 2.6% to about 3.5% LPC by weight based on the total weight of the lecithin; and (c) about 0.4% to about 0.6% PE by weight based on the total weight of the lecithin. The lipid system may comprise a lecithin, wherein the lecithin comprises (a) about 69% to about 77% PC by weight based on the total weight of the lecithin; (b) about 2.9% to about 3.3% LPC by weight based on the total weight of the lecithin; and about 0.45% to about 0.55% PE by weight based on the total weight of the lecithin. The lecithin may be substantially free of PA and PI.

[0080] The lipid system may consist essentially of a lecithin, wherein the lecithin comprises (a) about 50% to about 90% PC by weight based on the total weight of the lecithin; (b) about 2.3% to about 4% LPC by weight based on the total weight of the lecithin; and (c) about 0.3% to about 0.7% PE by weight based on the total weight of the lecithin. The lipid system may may consist essentially of a lecithin, wherein the lecithin comprises (a) about 62% to about 85% PC by weight based on the total weight of the lecithin; (b) about 2.6% to about 3.5% LPC by weight based on the total weight of the lecithin; and (c) about 0.4% to about 0.6% PE by weight based on the total weight of the lecithin. The lipid system may may consist essentially of a lecithin, wherein the lecithin comprises (a) about 69% to about 77% PC by weight based on the total weight of the lecithin; (b) about 2.9% to about 3.3% LPC by weight based on the total weight of the lecithin; and about 0.45% to about 0.55% PE by weight based on the total weight of the lecithin. The lecithin may be substantially free of PA and PI.

[0081] The lipid system comprised in a proliposome composition, including a nicotinamide riboside proliposome composition, may comprise sunflower lecithin, wherein the sunflower lecithin may comprise about 70% to about 80% phospholipid by weight based on the total weight of the sunflower lecithin.

[0082] The lipid system comprised in a proliposome composition, including a nicotinamide riboside proliposome composition, may comprise sunflower lecithin, wherein the sunflower lecithin may comprise:(a) about 69% to about 77% PC by weight based on the total weight of the phospholipid comprised in the sunflower lecithin;(b) about 2.9% to about 3.5% LPC by weight based on the total weight of the phospholipid comprised in the sunflower lecithin; and(c) about 0.45% to about 0.55% PE by weight based on the total weight of the phospholipid comprised in the sunflower lecithin.

[0083] The lipid system comprised in a proliposome composition, including a nicotinamide riboside proliposome composition, may comprise sunflower lecithin, wherein the sunflower lecithin may may be substantially free of PA and / or PI. The sunflower lecithin may comprise no more than 0.1% PA by weight based on the total weight of phospholipid comprised in the sunflower lecithin and / or no more than 0.1% PI by weight based on the total weight of the phospholipid comprised in the sunflower lecithin. The sunflower lecithin may comprise no more than 0.01% PA by weight based on the total weight of phospholipid comprised in the sunflower lecithin and / or no more than 0.01% PI by weight based on the total weight of phospholipid comprised in the sunflower lecithin. The sunflower lecithin may comprise no more than 0.001% PA by weight based on the totalweight of phospholipid comprised in the sunflower lecithin and / or no more than 0.001% PI by weight based on the total weight of phospholipid comprised in the sunflower lecithin.

[0084] The lipid system comprised in a proliposome composition, including a nicotinamide riboside proliposome composition, may consist essentially of sunflower lecithin, wherein the sunflower lecithin may may be substantially free of PA and / or PI. The lipid system may consist essentially of sunflower lecithin, wherein the sunflower lecithin may comprise no more than 0.1% PA by weight based on the total weight of phospholipid comprised in the sunflower lecithin and / or no more than 0.1% PI by weight based on the total weight of the phospholipid comprised in the sunflower lecithin. The lipid system may consist essentially of sunflower lecithin, wherein the sunflower lecithin may comprise no more than 0.01% PA by weight based on the total weight of phospholipid comprised in the sunflower lecithin and / or no more than 0.01% PI by weight based on the total weight of phospholipid comprised in the sunflower lecithin. The lipid system may consist essentially of sunflower lecithin, wherein the sunflower lecithin may comprise no more than 0.001 % PA by weight based on the total weight of phospholipid comprised in the sunflower lecithin and / or no more than 0.001% PI by weight based on the total weight of phospholipid comprised in the sunflower lecithin.

[0085] The phospholipid composition of the lipid system may be determined by known methods. Exemplary methods to determine the phospholipid composition of the lipid system include high-performance liquid chromatography (HPLC).

[0086] The proliposome composition may be free of added cholesterol, free of added synthetic non-ionic surfactant, and / or free of added polyethylene glycol (PEG). The proliposome composition may be free of added cholesterol, free of added synthetic non-ionic surfactant, and free of added polyethylene glycol (PEG).

[0087] DISPERSANT

[0088] A proliposome composition, including a nicotinamide riboside proliposome composition, comprises a dispersant. A dispersant may promote the even distribution and / or hydration of a proliposome composition in forming a liposome upon exposure to suitable conditions as described herein.

[0089] A proliposome composition, including a nicotinamide riboside proliposome composition, comprises a dispersant, wherein the composition comprises about 26% to about 45%, about 30% to about 41%, or about 34% to about 37%, dispersant by weight based on the total weight of the composition.

[0090] Exemplary dispersants include but are not limited to lactose, maltodextrin, mannitol, sorbitol, sucrose, trehalose, and xylitol.

[0091] A proliposome composition, including a nicotinamide riboside proliposome composition, comprises a dispersant, wherein the composition comprises about 26% to about 45%, about 30% to about 41%, or about 34% to about 37%, dispersant by weight based on the total weight of the composition. The proliposome composition, including the nicotinamide riboside proliposome composition, may comprise about 26% to about 45% dispersant by weight based on the total weight of the composition, wherein the dispersant may be one or more of lactose, maltodextrin, mannitol, sorbitol, sucrose, trehalose, and xylitol. The proliposome composition, including the nicotinamide riboside proliposome composition, may comprise about 30% to about 41% dispersant by weightbased on the total weight of the composition, wherein the dispersant may be one or more of lactose, maltodextrin, mannitol, sorbitol, sucrose, trehalose, and xylitol. The proliposome composition, including the nicotinamide riboside proliposome composition, may comprise about 34% to about 37%, dispersant by weight based on the total weight of the composition, wherein the dispersant may be one or more of lactose, maltodextrin, mannitol, sorbitol, sucrose, trehalose, and xylitol.

[0092] The proliposome composition, including the nicotinamide riboside proliposome composition, may comprise about 26% to about 45% dispersant by weight based on the total weight of the composition, wherein the dispersant may be maltodextrin. The proliposome composition, including the nicotinamide riboside proliposome composition, may comprise about 30% to about 41 % dispersant by weight based on the total weight of the composition, wherein the dispersant may be maltodextrin. The proliposome composition, including the nicotinamide riboside proliposome composition, may comprise about 34% to about 37%, dispersant by weight based on the total weight of the composition, wherein the dispersant may be maltodextrin.

[0093] EXCIPIENT

[0094] A proliposome composition, including a nicotinamide riboside proliposome composition, comprises an excipient. An excipient may promote the powder handling characteristic of the composition, including for a composition that is free flowing.

[0095] A proliposome composition, including a nicotinamide riboside proliposome composition, comprising an excipient, wherein the composition comprises about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition.

[0096] Exemplary excipients include, but are not limited to colloidal silica (anhydrous), corn starch, calcium carbonate, and magnesium stearate.

[0097] A proliposome composition, including a nicotinamide riboside proliposome composition, comprises about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition, wherein the excipient may be one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, and magnesium stearate. A proliposome composition, including a nicotinamide riboside proliposome composition, comprises about 1.4% to about 2.4% excipient by weight based on the total weight of the composition, wherein the excipient may be one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, and magnesium stearate. A proliposome composition, including a nicotinamide riboside proliposome composition, comprises about 1.6% to about 2.2% excipient by weight based on the total weight of the composition, wherein the excipient may be one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, and magnesium stearate. A proliposome composition, including a nicotinamide riboside proliposome composition, comprises about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition, wherein the excipient may be one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, and magnesium stearate.

[0098] A proliposome composition, including a nicotinamide riboside proliposome composition, comprises about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight basedon the total weight of the composition, wherein the excipient may be colloidal silica (anhydrous). A proliposome composition, including a nicotinamide riboside proliposome composition, comprises about 1.4% to about 2.4% excipient by weight based on the total weight of the composition, wherein the excipient may be colloidal silica (anhydrous). A proliposome composition, including a nicotinamide riboside proliposome composition, comprises about 1.6% to about 2.2% excipient by weight based on the total weight of the composition, wherein the excipient may be colloidal silica (anhydrous). A proliposome composition, including a nicotinamide riboside proliposome composition, comprises about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition, wherein the excipient may be colloidal silica (anhydrous).

[0099] ORGANIC SOLVENT

[0100] A proliposome composition, including a nicotinamide riboside proliposome composition, may comprise an organic solvent. The organic solvent may be help in the preparation of a homogenous powder.

[0101] A proliposome composition, including a nicotinamide riboside proliposome composition, comprises no more than about 2%, about 0.5% to about 2%, no more than about 1.5%, or about 0.5% to about 1.5%, organic solvent by weight based on the total weight of the composition.

[0102] An exemplary organic solvent may be ethanol.

[0103] A proliposome composition, including a nicotinamide riboside proliposome composition, comprises no more than about 2%, about 0.5% to about 2%, no more than about 1.5%, or about 0.5% to about 1.5%, organic solvent by weight based on the total weight of the composition, wherein the organic solvent may be ethanol. A proliposome composition, including a nicotinamide riboside proliposome composition, comprises no more than about 2% organic solvent by weight based on the total weight of the composition, wherein the organic solvent may be ethanol. A proliposome composition, including a nicotinamide riboside proliposome composition, comprises about 0.5% to about 2% organic solvent by weight based on the total weight of the composition, wherein the organic solvent may be ethanol. A proliposome composition, including a nicotinamide riboside proliposome composition, comprises no more than about 1.5% organic solvent by weight based on the total weight of the composition, wherein the organic solvent may be ethanol. A proliposome composition, including a nicotinamide riboside proliposome composition, comprises about 0.5% to about 1.5% organic solvent by weight based on the total weight of the composition, wherein the organic solvent may be ethanol.

[0104] ACTIVE INGREDIENT

[0105] The proliposome composition comprises one or more active ingredients. The active ingredient is not particularly limited. The proliposome composition comprises one or more active ingredients, wherein the one or more active ingredients may be one or more hydrophilic active ingredients and / or one or more lipophilic active ingredients. Exemplary active ingredients include vitamins, peptides, antioxidants (Resveratrol), flavonoids (quercetin, fisetin, myricetin, apigenin, and naringenin), plant extracts (Ashwagandha), spermidine. Plant extracts may be comprised of both hydrophilic active ingredients and hydrophilic active ingredients. Exemplary active ingredients include a nicotinamide riboside salt (e.g. chloride, malate, tartrate), nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR). The active ingredient may beone or more of a nicotinamide riboside salt (e.g. chloride, malate, tartrate), NMN, NaMN, and NaR. The active ingredient may be one or more of nicotinamide riboside chloride, NMN, NaMN, and NaR. The active ingredient may be a nicotinamide riboside salt (e.g. chloride, malate, tartrate) and one or more of NMN, NaMN, and NaR. The active ingredient may be nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.

[0106] Exemplary lipophilic active ingredients include but are not limited to vitamins such as vitamins A, D, E, and K; ubiquinone; flavonoids such as quercetin, fisetin, myricetin, apigenin, and naringenin; and antioxidants such as resveratrol.

[0107] Exemplary hydrophilic active ingredients include but are not limited to salt forms of nicotinamide riboside such as nicotinamide riboside chloride, nicotinamide riboside malate, nicotinamide riboside tartrate; vitamins such as vitamins B and C; peptides such as glutathione and hydrolyzed collagen peptides; hyaluraonic acid; and spermidine. Exemplary hydrophilic active ingredients include a nicotinamide riboside salt (e.g. chloride, malate, tartrate), nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR). The hydrophilic active ingredient may be one or more of a nicotinamide riboside salt (e.g. chloride, malate, tartrate), NMN, NaMN, and NaR. The hydrophilic active ingredient may be one or more of nicotinamide riboside chloride, NMN, NaMN, and NaR. The hydrophilic active ingredient may be a nicotinamide riboside salt (e.g. chloride, malate, tartrate) and one or more of NMN, NaMN, and NaR. The hydrophilic active ingredient may be nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.

[0108] AN NAD+ RELATED COMPOUND AS THE ACTIVE INGREDIENT

[0109] A NAD+ related compound as used herein may increase the NAD+ levels (e.g. plasma concentration) when administered to a subject. The proliposome composition may comprise a NAD+ related compound as the active ingredient. The proliposome composition may comprise one or more NAD+ related compound as the active ingredient.

[0110] The NAD+ related compound may be a nicotinamide riboside salt (e.g. chloride, malate, tartrate), nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR). When the proliposome composition comprises a NAD+ related compound as an active ingredient, the NAD+ compound may be one or more of a nicotinamide riboside salt (e.g. chloride, malate, tartrate), NMN, NaMN, and NaR. When the proliposome composition comprises a NAD+ related compound as an active ingredient, the NAD+ compound may be one or more of nicotinamide riboside chloride, NMN, NaMN, and NaR. When the proliposome composition comprises a NAD+ related compound as an active ingredient, the NAD+ compound may be a nicotinamide riboside salt (e.g. chloride, malate, tartrate) and one or more of NMN, NaMN, and NaR. When the proliposome composition comprises a NAD+ related compound as an active ingredient, the NAD+ compound may be nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.

[0111] NICOTINAMIDE RIBOSIDE CHLORIDE AS THE ACTIVE INGREDIENT

[0112] Nicotinamde riboside, 3-Carbamoyl-1-(P-D-ribofuranosyl)pyridin-1-ium or 3-Carbamoyl-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium or CAS Registry Number 1341-23-7, which may be depicted as shown below:NHHOHO

[0113] The chloride salt of nicotinamide riboside, referred to as nicotinamide riboside chloride, has a chloride (Cl ) counterion (CAS Registry Number 23111-00-4). Nicotinamide riboside chloride may be the active ingredient in any proliposome composition disclosed herein.

[0114] ALTERNATIVE WATER SOLUBLE SALT OF NICOTINAMIDE RIBOSIDE

[0115] Alternative water soluble salts of nicotinamide riboside, include but are not limited to, but not limited to nicotinamide riboside malate and nicotinamide riboside tartrate.

[0116] A nicotinamide riboside proliposome composition comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition. The composition may further comprise no more than about 2% organic solvent by weight based on the total weight of the composition. The nicotinamide riboside chloride may be replaced with an alternative water-soluble salt of nicotinamide riboside. The nicotinamide riboside chloride may be replaced with an alternative water-soluble salt of nicotinamide riboside, wherein the alternative water soluble salt of nicotinamide riboside may be nicotinamide riboside tartrate and / or nicotinamide malate. The nicotinamide riboside chloride may be replaced with an alternative water-soluble salt of nicotinamide riboside, wherein the alternative water-soluble salt of nicotinamide riboside may be a combination of (a) nicotinamide riboside chloride and (b) nicotinamide riboside tartrate and / or nicotinamide malate. The alternative water-soluble salt of nicotinamide riboside may replace nicotinamide riboside chloride in any nicotinamide riboside proliposome composition herein described.

[0117] METHODS OF PREPARATION

[0118] The inventor have surprisingly found a method of preparing a proliposome composition, including a nicotinamide riboside proliposome composition, wherein the method includes a minimal number of steps without heating of the ingredients. The proliposome composition may provide improved bioavailability of the active ingredient, including nicotinamide riboside chloride, upon administration to a subject.

[0119] The methods of preparation may be carried out at room temperature (about 20°C to about 25°C). Therefore, the method may be advantageously applied to active ingredients that may be sensitive to, e.g. degradation, at elevated temperatures.

[0120] The method of preparation may be carried out a relative humidity of about 50% to about 65%.

[0121] The proliposome compositions may be prepared with a minimal number of ingredients. Therefore, the proliposome composition may be suitable for a wide range of subjects, including subjects with a sensitivity to chemicals that may be included in compositions for consumption and / or aversion to chemicals of animal origin.

[0122] A proliposome composition as described herein may be prepared by a method comprising:(a) preparing a first mixture of an organic solvent and a lipid system as herein described;(b) spraying the first mixture onto an active ingredient to form a second mixture, wherein the spraying is airless spraying;(c) adding to the second mixture a dispersant to form a third mixture; and(d) adding to the third mixture an excipient to form a final mixture.The method may be carried out without the addition of liquid other than the liquid comprised in the first mixture. The method may be carried out at room temperature (about 20°C to about 25°C). The method may be carried out at a relative humidity of about 50% to about 65%. Thereby a proliposome composition is prepared.

[0123] The first mixture of the organic solvent and the lipid system may have a ratio of lipid system to organic solvent of 5:1 to 2.2: 1, 4.5: 1 to 2.8:1, or 4.2:1 to 3.2:1. The first mixture of the organic solvent and the lipid system may have a ratio of lipid system to organic solvent of about 4 to about 1.

[0124] The proliposome composition may be prepared in a high shear mixer. The spraying of the first mixture in (b) may be sprayed onto the active ingredient in a high shear mixer. The dispersant addition in (c) may be added in a high shear mixer. The excipient addition in (d) may be added in a high shear mixer. The final mixture may be mixed in a high shear mixer.

[0125] When the proliposome composition comprises more than one active ingredient, the active ingredients may be mixed, e.g. mixed in a high shear mixer, to form an active ingredient premix. The first mixture may then be sprayed onto the active ingredients premix to form the second mixture.

[0126] A proliposome composition as described herein may be prepared by a method comprising:(a) (1) preparing a first mixture of an organic solvent and a lipid system as herein described;(a) (2) preparing a mixture of two or more active ingredients to for a premix of active ingredients;(b) spraying the first mixture onto the premix of active ingredients to form a second mixture, wherein the spraying is airless spraying;(c) adding to the second mixture a dispersant to form a third mixture; and(d) adding to the third mixture an excipient to form a final mixture.The method may be carried out without the addition of liquid other than the liquid comprised in the first mixture. The method may be carried out at room temperature (about 20°C to about 25°C). The method may be carried out at a relative humidity of about 50% to about 65%. Thereby a proliposome composition is prepared. The firstmixture of the organic solvent and the lipid system may have a ratio of lipid system to organic solvent of 5:1 to 2.2: 1, 4.5: 1 to 2.8:1, or 4.2:1 to 3.2:1. The first mixture of the organic solvent and the lipid system may have a ratio of lipid system to organic solvent of about 4:1.

[0127] A proliposome composition may be prepared by a method comprising or consisting essentially of: (a) preparing a first mixture of an organic solvent and a lipid system as herein described;(a’) adding an active ingredient into a high shear mixer;(b) spraying the first mixture onto the active ingredient to form a second mixture, wherein the spraying is airless spraying;(b’) mixing the second mixture in the high shear mixer;(c) adding to the second mixture a dispersant to form a third mixture;(c’) mixing the third mixture in the high shear mixer;(d) adding to the third mixture an excipient to form a final mixture; and(d’) mixing the final mixture in the high shear mixer;wherein(i) the method is carried out at about 20°C to about 25°C; and(ii) the mixing in each of (b’), (c’), and (d’) is no more than 10 minutes.The method may be carried out without the addition of liquid other than the liquid comprised in the first mixture. The mixing of each of (b’), (c’), and (d’) may be no more than 5 minutes.The mix speed of the high shear mixer may be about 100 rotations per minute (rpm). The blade speed of the high shear mixer may be about 2000 rpm.The method may be carried out at a relative humidity of about 50% to about 65%.The first mixture of the organic solvent and the lipid system may have a ratio of lipid system to organic solvent of 5:1 to 2.2: 1, 4.5: 1 to 2.8:1, or 4.2:1 to 3.2:1. The first mixture of the organic solvent and the lipid system may have a ratio of lipid system to organic solvent of about 4:1.When the proliposome composition comprises more than one active ingredient, the active ingredients may be mixed, e.g. mixed in a high shear mixer, to form an active ingredient premix in (a’). The active ingredient premix may be mixed in a high shear mixer for no more than about 10 minutes or no more than about 5 minutes. The first mixture may then be sprayed onto the active ingredients premix to form the second mixture in (b).

[0128] The proliposome composition may be prepared in a high shear mixer. The spraying of the first mixture in (b) may be sprayed onto the active ingredient in a high shear mixer. The dispersant addition in (c) may be added in a high shear mixer. The excipient addition in (d) may be added in a high shear mixer. The final mixture may be mixed in a high shear mixer.

[0129] A proliposome composition may be prepared by a method comprising or consisting essentially of: (a) preparing a first mixture of an organic solvent and a lipid system as herein described;(a’) adding one or more active ingredients into a high shear mixer, wherein when the active ingredient comprises two or more active ingredients, the two or more active ingredients are added into the high shear mixer and to form a premix of active ingredients;(b)(1) spraying the first mixture onto the active ingredient to form a second mixture, wherein the spraying is airless spraying, or(2) spraying the first mixture onto the premix of active ingredients to form the second mixture, wherein the spraying is airless spraying;(b’) mixing the second mixture in the high shear mixer;(c) adding to the second mixture a dispersant to form a third mixture;(c’) mixing the third mixture in the high shear mixer;(d) adding to the third mixture an excipient to form a final mixture; and(d’) mixing the final mixture in the high shear mixer;wherein(i) the method is carried out at about 20°C to about 25°C; and(ii) the mixing in each of (b’), (c’), and (d’) is no more than 10 minutes.The method may be carried out without the addition of liquid other than the liquid comprised in the first mixture. The mixing of each of (b’), (c’), and (d’) may be no more than 5 minutes. The mixing of the two or more active ingredients to form a premix of active ingredients may be no more than 10 minutes or no more than 5 minutes. The mix speed of the high shear mixer may be about 100 rpm. The blade speed of the high shear mixer may be about 2000 rpm. The method may be carried out at a relative humidity of about 50% to about 65%. The first mixture of the organic solvent and the lipid system may have a ratio of lipid system to organic solvent of 5:1 to 2.2: 1, 4.5: 1 to 2.8:1, or 4.2:1 to 3.2:1. The first mixture of the organic solvent and the lipid system may have a ratio of lipid system to organic solvent of about 4:1.

[0130] Airless spraying allows for the distribution of the lipid system over the active ingredient with minimal liquid allowing a free-flowing powder to be produced at room temperature without heating. The nozzle size may be from about 10 m to about 450 pm.

[0131] The method of preparing a proliposome composition produces a proliposome composition that may have a mean particle size of no more than about 400 pm, no more than about 350 pm, or no more than about 300 pm. The method of preparing a proliposome composition produces a proliposome composition that may have a mean particle size of no more than about 300 pm. The method of preparing a proliposome composition produces a proliposome composition that may have a mean particle size of no more than about 300 pm, wherein the Dio may be less than about 100 pm, the D50 may be less than about 200 pm, and the D90 may be less than about 400 pm.

[0132] The method of preparing a proliposome composition, wherein the active ingredient is nicotinamide riboside chloride, produces nicotinamide riboside proliposome composition that may have a mean particle size ofno more than about 400 pm, no more than about 350 pm, or no more than about 300 pm. The method of preparing a proliposome composition, wherein the active ingredient is nicotinamide riboside chloride, produces nicotinamide riboside proliposome composition that may have a mean particle size of no more than about 300 pm. The method of preparing a proliposome composition, wherein the active ingredient is nicotinamide riboside chloride, produces nicotinamide riboside proliposome composition that may have a mean particle size of no more than about 300 pm, wherein the Dio may be less than about 100 pm, the D50 may be less than about 200 pm, and the D90 may be less than about 400 pm

[0133] The method of preparing a proliposome composition produces a proliposome composition that when 100 mg of the proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) of less than about 400 nm, less than about 350 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, or less than about 50 nm. The method of preparing a proliposome composition produces a proliposome composition that when 100 mg of the proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) less than about 300 nm. The method of preparing a proliposome composition produces a proliposome composition that when 100 mg of the proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) less than about 50 nm.

[0134] The method of preparing a proliposome composition, wherein the active ingredient is nicotinamide riboside chloride, produces a nicotinamide riboside proliposome composition that when 100 mg of the proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) of less than about 400 nm, less than about 350 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, or less than about 50 nm. The method of preparing a proliposome composition, wherein the active ingredient is nicotinamide riboside chloride, produces a nicotinamide riboside proliposome composition when 100 mg of the proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) less than about 300 nm. The method of preparing a proliposome composition, wherein the active ingredient is nicotinamide riboside chloride, produces a nicotinamide riboside proliposome composition when 100 mg of the proliposome composition is mixed with 100 ml of water, the resulting liposome may have a liposomal particle size (Z-average (d.nm)) less than about 50 nm.

[0135] SHELF STABLE PROLIPOSOME COMPOSITION

[0136] The proliposome composition, including a nicotinamide riboside proliposome composition, may be shelf stable. As used herein “shelf stable” refers to a proliposome composition wherein after a specified time in a sealed container, the proliposome composition maintains one or more of the characteristics of the proliposome composition as prepared. Exemplary characteristics may be one or more of appearance of the proliposome composition (e.g. color, powder), which may be assessed visually; solubility in water (e.g. 500 mg of proliposome composition disperses as colloidal solution in 250 ml of water); no more than 5% loss on drying, particle size of the composition, which may be assessed as herein described, and liposomal particle size (e.g. when 100 mg ofproliposome composition is dispersed in 100 ml of water), which may be assessed as herein described), and identification, which may be assessed by Fourier Transform Infrared (FTIR) spectroscopy.

[0137] The proliposome composition, including a nicotinamide composition, may be shelf stable for about 3 months at a temperature of about 20°C to about 25°C.

[0138] The proliposome composition, including a nicotinamide riboside proliposome composition may be shelf stable for about 6 months at a temperature of about 20°C to about 25°C.

[0139] The proliposome composition, including a nicotinamide riboside proliposome composition may be shelf stable for about 12 months at a temperature of about 20°C to about 25°C.

[0140] FORMULATION OF PROLIPOSOME COMPOSITION

[0141] The proliposome composition, including the nicotinamide riboside proliposome composition, may be formulated for oral administration. The proliposome composition may be formulated into a tablet (e.g. chewable tablet, orally disintegrating tablet, enterically coated tablet) or a capsule. The proliposome composition, including the nicotinamide riboside composition, may be formulation for oral administration wherein the formulation allows the proliposome composition to form a liposome in the mouth. The proliposome composition, including the nicotinamide riboside composition, may be a formulation for oral administration wherein the formulation allows the proliposome composition to form a liposome in the stomach.

[0142] In formulating the proliposome composition, including the nicotinamide riboside proliposome composition, for oral administration the prepared proliposome composition may be combined with further formulating excipients. As used herein “formulating excipients” refers to excipients that are combined with a proliposome composition prepared as described throughout this description. Exemplary formulating excipients include, but are not limited to colloidal silica (anhydrous), corn starch, calcium carbonate, magnesium stearate, dicalcium phosphate dihydrate, hypromellose, and microcrystalline cellulose.

[0143] The oral formulation comprising a proliposome composition, including the nicotinamide riboside proliposome composition, may comprise no more than about 50%, no more than about 40%, nor more than about 30%, no more than about 20%, or no more than about 10% by weight formulating excipient based on the total weight of the oral formulation. The formulating excipient may be one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, magnesium stearate, dicalcium phosphate dihydrate, hyprome Hose, and microcrystalline cellulose.

[0144] USE OF THE NICOTINAMIDE RIBOSIDE PROLIPOSOME COMPOSITION

[0145] The inventor believes that the ability to more effectively boost NAD+ by administration of the nicotinamide riboside proliposome composition may contribute to correcting and / or avoiding the age-related decreases in NAD+. Increasing NAD+ is proposed as a therapy for age related diseases, see e.g. Li et al., Neurosci Bull (Feb 2024) 40(2): 218; Abdellatif et al., Circulation (2021) 144:1795. The superior delivery of nicotinamide riboside by the nicotinamide riboside proliposome composition, and the consequential boost in NAD+, may find across diseases, conditions, and / or symptoms associated with aging and / or diseases, conditions, and / or symptoms associated with aging-related decreases in NAD+. Moreover, the proliposome composition mayhave a minimal of ingredients and may be less of a concern in their administration at high doses and / over long periods of time.

[0146] The nicotinamide riboside proliposome composition as described herein may be for use as a nutritional supplement. The nicotinamide riboside proliposome composition as described herein may be for use as a medicament.

[0147] The nicotinamide riboside proliposome composition may be for use in increasing NAD+ in a subject. Provided is a method of increasing NAD+ in a subject, comprising administering to the subject the nicotinamide riboside proliposome composition. Provided is use of the nicotinamide riboside proliposome composition in the manufacture of a medicament for increasing NAD+ in a subject in a subject. The subject may be overweight or obese. The subject may have diabetes, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0148] An overweight or obese subject may be determined on the basis of World Health Organization standards, see, e.g. Obesity and Overweight (WORLD WIDE WEB at who.int / news-room / fact-sheets / detail / obesity-and-overweight), from which the criteria in Table 1 have been taken.

[0149] Table 1 : Overweight and Obese CriteriaSubject Overweight ObeseAdult (aged > 19 years) BMI greater than or equal to 25 BMI greater than or equal to 30BMI-for-age greater than 1 standard greater than 2 standard deviations Child aged between 5- deviation above the WHO Growth above the WHO Growth Reference 19 yearsReference median medianweight-for-height greater than 2 weight-for-height greater than 3 Child aged < 5 years standard deviations above WHO Child standard deviations above the WHO Growth Standards median Child Growth Standards medianBody mass index (BMI): weight (kg) / height2(m2), where the mass index is a surrogate marker of fatness. The child growth standards are found at WORLD WIDE WEB atwho.int / tools / child-growth-standards.

[0150] The nicotinamide riboside proliposome composition may be for use in mitigating age-related decreases in NAD+ in a subject. Provided is a method of mitigating age-related decreases in NAD+ in a subject, comprising administering to the subject the nicotinamide riboside proliposome composition. Provided is use of the nicotinamide riboside proliposome composition in the manufacture of a medicament for mitigating age-related decreases in NAD+ in a subject. The subject may be overweight or obese. The subject may have diabetes, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0151] The nicotinamide riboside proliposome composition may be for use in mitigating a disease, condition, and / or symptom associated with aging in a subject. The nicotinamide riboside proliposome composition may be for use in mitigating a disease, condition, and / or symptom associated with aging in a subject, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. Provided is a method of mitigating a disease,condition, and / or symptom associated with aging in a subject, comprising administering to the subject the nicotinamide riboside proliposome composition. Provided is a method of mitigating a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the nicotinamide riboside proliposome composition, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. The disease, condition and / or symptom of aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer. The disease, condition, and / or symptom of aging, wherein the disease condition and / or symptom is linked to decreased NAD+, may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0152] The nicotinamide riboside proliposome composition may be for use in delaying the onset of a disease, condition, and / or symptom associated with aging in a subject. The nicotinamide riboside proliposome composition may be for use in delaying the onset of a disease, condition, and / or symptom associated with aging in a subject, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. Provided is a method of delaying the onset of a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the nicotinamide riboside proliposome composition. Provided is a method of delaying the onset of a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the nicotinamide riboside proliposome composition, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. The disease condition and / or symptom of aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer. The disease, condition, and / or symptom of aging, wherein the disease condition and / or symptom is linked to decreased NAD+, diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0153] The nicotinamide riboside proliposome composition may be for use in treating a disease, condition, and / or symptom associated with aging in a subject. The nicotinamide riboside proliposome composition may be for use in treating a disease, condition, and / or symptom associated with aging in subject, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. Provided is a method of treating a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the nicotinamide riboside proliposome composition. Provided is a method of treating a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the nicotinamide riboside proliposome composition, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. The disease condition and / or symptom of aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer. The disease, condition, and / or symptom of aging, wherein the disease condition and / or symptom is linked to decreased NAD+, may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0154] The nicotinamide riboside proliposome composition may be for use in dietary management of a disease, condition, and / or symptom associated with aging in a subject. The nicotinamide riboside proliposome composition may be for use in dietary management of a disease, condition, and / or symptom associated with aging in subject, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. Provided is a method of dietary management of a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the nicotinamide riboside proliposome composition. Provided is a method of dietary management of a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the nicotinamide riboside proliposome composition, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. The disease condition and / or symptom of aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer. The disease, condition, and / or symptom of aging, wherein the disease condition and / or symptom is linked to decreased NAD+, may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0155] Provide is a method of(a) increasing NAD+;(b) mitigating age-related decreases in NAD+;(c) mitigating a disease, condition, and / or symptom associated with aging,(d) delaying the onset of a disease, condition, and / or symptom associated with aging;(e) treating a disease, condition, and / or symptom associated with aging; or(f) dietary management of a disease, condition, and / or symptom associated with aging;in a subject in need therefor, comprising administering a therapeutically effective amount of a nicotinamide riboside proliposome composition.The subject in need thereof of (a) or (b) may be overweight or obese. The subject in need thereof of (a) or (b) may may have diabetes, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.The disease, condition and / or symptom associated with aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0156] Provide is use of a nicotinamide riboside proliposome composition in the manufacture of a medicament for(a) increasing NAD+;(b) mitigating age-related decreases in NAD+;(c) mitigating a disease, condition, and / or symptom associated with aging,(d) delaying the onset of a disease, condition, and / or symptom associated with aging;(e) treating a disease, condition, and / or symptom associated with aging; or(f) dietary management of a disease, condition, and / or symptom associated with aging;in a subject.The subject of (a) or (b) may be overweight or obese. The subject of (a) or (b) may may have diabetes, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer. The disease, condition and / or symptom associated with aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0157] USE OF THE PROLIPOSOME COMPOSITION COMPRISING A NAD+ RELATED COMPOUND OF THE ACTIVE INGREDIENT

[0158] When the proliposome composition comprises a NAD+ related compound as an active ingredient, the NAD+ compound may be one or more of a nicotinamide riboside salt (e.g. chloride, malate, tartrate), nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR). When the proliposome composition comprises a NAD+ related compound as an active ingredient, the NAD+ compound may be one or more of nicotinamide riboside chloride, NMN, NaMN, and NaR. When the proliposome composition comprises a NAD+ related compound as an active ingredient, the NAD+ compound may be a nicotinamide riboside salt (e.g. chloride, malate, tartrate) and one or more of NMN, NaMN, and NaR. When the proliposome composition comprises a NAD+ related compound as an active ingredient, the NAD+ compound may be nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.

[0159] The proliposome composition comprising a NAD+ related compound may be for use in mitigating age-related decreases in NAD+ in a subject. Provided is a method of mitigating age-related decreases in NAD+ in a subject, comprising administering to the subject a proliposome composition comprising a NAD+ related compound. Provided is use of a proliposome composition comprising a NAD+ related compound in the manufacture of a medicament for mitigating age-related decreases in NAD+ in a subject. The subject may be overweight or obese. The subject may have diabetes, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0160] The proliposome composition comprising a NAD+ related compound may be for use in mitigating a disease, condition, and / or symptom associated with aging in a subject. The proliposome composition comprising a NAD+ related compound may be for use in mitigating a disease, condition, and / or symptom associated with aging in a subject, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. Provided is a method of mitigating a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the proliposome composition comprising a NAD+ related compound. Provided is a method of mitigating a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the proliposome composition comprising a NAD+ related compound, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. The disease, condition and / or symptom of aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer. The disease, condition, and / or symptom of aging, wherein the disease condition and / or symptom is linked to decreased NAD+, may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0161] The proliposome composition comprising a NAD+ related compound may be for use in delaying the onset of a disease, condition, and / or symptom associated with aging in a subject. The proliposome composition comprising a NAD+ related compound n may be for use in delaying the onset of a disease, condition, and / or symptom associated with aging in a subject, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. Provided is a method of delaying the onset of a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the proliposome composition comprising a NAD+ related compound. Provided is a method of delaying the onset of a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the proliposome composition comprising a NAD+ related compound, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. The disease condition and / or symptom of aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer. The disease, condition, and / or symptom of aging, wherein the disease condition and / or symptom is linked to decreased NAD+, diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0162] The proliposome composition comprising a NAD+ related compound may be for use in treating a disease, condition, and / or symptom associated with aging in a subject. The proliposome composition comprising a NAD+ related compound may be for use in treating a disease, condition, and / or symptom associated with aging in subject, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. Provided is a method of treating a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the proliposome composition comprising a NAD+ related compound. Provided is a method of treating a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the proliposome composition comprising a NAD+ related compound, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. The disease condition and / or symptom of aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer. The disease, condition, and / or symptom of aging, wherein the disease condition and / or symptom is linked to decreased NAD+, may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0163] The proliposome composition comprising a NAD+ related compound may be for use in dietary management of a disease, condition, and / or symptom associated with aging in a subject. The proliposome composition comprising a NAD+ related compound may be for use in dietary management of a disease, condition, and / or symptom associated with aging in subject, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. Provided is a method of dietary management of a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the proliposome composition comprising a NAD+ related compound. Provided is a method of dietary management of a disease, condition, and / or symptom associated with aging in a subject, comprising administering to the subject the proliposomecomposition comprising a NAD+ related compound, wherein the disease, condition, and / or symptom may be linked to decreased NAD+. The disease condition and / or symptom of aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer. The disease, condition, and / or symptom of aging, wherein the disease condition and / or symptom is linked to decreased NAD+, may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0164] Provide is a method of(a) increasing NAD+;(b) mitigating age-related decreases in NAD+;(c) mitigating a disease, condition, and / or symptom associated with aging,(d) delaying the onset of a disease, condition, and / or symptom associated with aging;(e) treating a disease, condition, and / or symptom associated with aging; or(f) dietary management of a disease, condition, and / or symptom associated with aging;in a subject in need therefor, comprising administering a therapeutically effective amount of a proliposome composition comprising a NAD+ related compound.The subject in need thereof of (a) or (b) may be overweight or obese. The subject in need thereof of (a) or (b) may may have diabetes, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.The disease, condition and / or symptom associated with aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0165] Provide is use of a proliposome composition comprising a NAD+ related compound in the manufacture of a medicament for(a) increasing NAD+;(b) mitigating age-related decreases in NAD+;(c) mitigating a disease, condition, and / or symptom associated with aging,(d) delaying the onset of a disease, condition, and / or symptom associated with aging;(e) treating a disease, condition, and / or symptom associated with aging; or(f) dietary management of a disease, condition, and / or symptom associated with aging;in a subject.The subject of (a) or (b) may be overweight or obese. The subject of (a) or (b) may may have diabetes, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer. The disease, condition and / or symptom associated with aging may be diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

[0166] DOSE OF THE NICOTINAMIDE RIBOSIDE PROLIPOSOME COMPOSITION

[0167] A subject may be administered a daily dose of the nicotinamide riboside proliposome composition in an amount of about 250 mg of nicotinamide riboside. A subject may be administered a daily dose of the nicotinamide riboside proliposome composition in an amount of about 250 mg to 1000 mg of nicotinamide riboside.

[0168] A daily dose may be administered in one or more doses. When a daily dose is delivered in more than one dose, it may be administered throughout the day. A daily dose may be administered in one, two, three, or four doses.

[0169] For example, when a daily dose is 250 mg of nicotinamide riboside, the nicotinamide riboside proliposome composition may be delivered in one does, wherein the one dose delivers about 250 mg nicotinamide riboside.

[0170] For example, when a daily dose is 1000 mg of nicotinamide riboside, the nicotinamide riboside proliposome composition may be delivered in four doses, wherein each dose delivered about 250 mg nicotinamide riboside.

[0171] All references cited herein, including patents, patent applications, publications, and databases, are hereby incorporated by reference in their entireties, whether previously specifically incorporated or not.

[0172] Various modifications and variations of the described method and compositions of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific disclosure, it will be understood that it is capable of further modifications and that the invention as claimed should not be unduly limited to such specific disclosure. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art are intended to be within the scope of the invention. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known customary practice within the art to which the invention pertains and may be applied to the essential features herein before set forth.

[0173] It is to be understood that any particular disclosure may be explicitly excluded from any one or more of the claims. Where ranges are given, any value within the range may explicitly be excluded from any one or more of the claims. Any element, feature, or application of the preparations, medicaments, compositions and / or methods of the disclosure, can be excluded from any one or more claims. For purposes of brevity, all of the descriptions in which one or more elements, features, purposes, or aspects is excluded are not set forth explicitly herein.

[0174] The reference to any prior art in this specification is not, and should not be taken as, an acknowledgement or any form of suggestion that the prior art forms part of the common general knowledge in the field in Australia or elsewhere.ITEMS

[0175] Further attributes and features of the invention can be understood by reference to the following numbered items. Reference to disclosure in any of the preceding disclosure is applicable to any of the followingnumbered items and to any combination of any number of the following items, as recognized by appropriate antecedent disclosure in any combination that can be made.

[0176] For the avoidance of doubt, (1) when the phrase, for example, “of ITEM 17 or ITEM 18” is recited, it means that it applies equally and individually to each of the recited items; (2) when the phase, for example, “any one of ITEM 3 to ITEM 6” is recited, it means that it applies equally and individually to each of the ITEM numbers bounding the range as well as the ITEM numbers included in the range, i.e. each of ITEM 3, ITEM 4, ITEM 5, and ITEM 6; and (3) when the phrase, for example, “any one of the preceding ITEMS”, it means that it applies equally and individually to each of the ITEM numbers that come before that ITEM.

[0177] The following numbered items are provided:ITEM 1. A method of increasing NAD+ in a subject comprising administering to the subject a nicotinamide riboside proliposome composition, wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 2. A nicotinamide riboside proliposome composition for use in increasing NAD+ in a subject, wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 3. Use of a nicotinamide riboside proliposome composition in the manufacture of a medicament for increasing NAD+ in a subject, wherein the composition comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 4. A method of mitigating age-related decreases in NAD+ in a subject comprising administering to the subject a nicotinamide riboside proliposome composition, wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 5. A nicotinamide riboside proliposome composition for use in mitigating age-related decreases in NAD+ in a subject, wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 6. Use of a nicotinamide riboside proliposome composition in the manufacture of a medicament for mitigating age-related decreases in NAD+ in a subject, wherein the composition comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 7. A method of increasing NAD+ in a subject comprising administering to the subject a proliposome composition, wherein the comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 8. A proliposome composition for use in increasing NAD+ in a subject, wherein the proliposome comprises: (a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 9. Use of a proliposome composition in the manufacture of a medicament for increasing NAD+ in a subject, wherein the composition comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 10. A method of mitigating age-related decreases in NAD+ in a subject comprising administering to the subject a proliposome composition, wherein the proliposome comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 11. A proliposome composition for use in mitigating age-related decreases in NAD+ in a subject, wherein the proliposome comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 12. Use of a proliposome composition in the manufacture of a medicament for mitigating age-related decreases in NAD+ in a subject, wherein the composition comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 13. The method, composition, or use of any one of ITEM 7 to ITEM 12, wherein the NDA+ related compound comprises one or more of nicotinamide riboside chloride, a water soluble salt of nicotinamide riboside, nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR). ITEM 14. The method, composition, or use of ITEM 13, wherein the NDA+ related compound comprises nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.ITEM 15. The method, composition, or use of any one of ITEM 1 to ITEM 14, wherein the subject is overweight or obese.ITEM 16. The method, composition, or use of any one of ITEM 1 to ITEM 15, wherein the subject has diabetes, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.ITEM 17. A method of mitigating a disease, condition, and / or symptom associated with aging in a subject comprising administering to the subject a nicotinamide riboside proliposome composition, wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 18. A nicotinamide riboside proliposome composition for use in mitigating a disease, condition, and / or symptom associated with aging in a subject, wherein the nicotinamide riboside proliposome comprises: (a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the compositionITEM 19. Use of a nicotinamide riboside proliposome composition in the manufacture of a medicament for mitigating a disease, condition, and / or symptom associated with aging in a subject, wherein the composition comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 20. A method of mitigating a disease, condition, and / or symptom associated with aging in a subject comprising administering to the subject a proliposome composition, wherein the proliposome comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 21. A proliposome composition for use in mitigating a disease, condition, and / or symptom associated with aging in a subject, wherein the proliposome comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the compositionITEM 22. Use of a proliposome composition in the manufacture of a medicament for mitigating a disease, condition, and / or symptom associated with aging in a subject, wherein the composition comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 23. The method, composition, or use of any one of ITEM 20 to ITEM 22, wherein the NDA+ related compound comprises one or more of nicotinamide riboside chloride, a water soluble salt of nicotinamide riboside, nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR). ITEM 24. The method, composition, or use of ITEM 23, wherein the NDA+ related compound comprises nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.ITEM 25. The method, composition, or use of any one of ITEM 17 to ITEM 24, wherein the disease, condition, and / or symptom is linked to decreased NAD+.ITEM 26. The method, composition, or use of any one of ITEM 17 to ITEM 25, wherein the disease, condition, and / or symptom is one or more of diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and cancer.ITEM 27. A method of delaying the onset of a disease, condition, and / or symptom associated with aging in a subject comprising administering to the subject a nicotinamide riboside proliposome composition, wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 28. A nicotinamide riboside proliposome composition for use in delaying the onset of a disease, condition, and / or symptom associated with aging in a subject, wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 29. Use of a nicotinamide riboside proliposome composition in the manufacture of a medicament for delaying the onset of a disease, condition, and / or symptom associated with aging in a subject, wherein the composition comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 30. A method of delaying the onset of a disease, condition, and / or symptom associated with aging in a subject comprising administering to the subject a proliposome composition, wherein the proliposome comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 31. A proliposome composition for use in delaying the onset of a disease, condition, and / or symptom associated with aging in a subject, wherein the proliposome comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 32. Use of a proliposome composition in the manufacture of a medicament for delaying the onset of a disease, condition, and / or symptom associated with aging in a subject, wherein the composition comprises: (a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 33. The method, composition, or use of any one of ITEM 30 to ITEM 32, wherein the NDA+ related compound comprises one or more of nicotinamide riboside chloride, a water soluble salt of nicotinamide riboside, nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR). ITEM 34. The method, composition, or use of ITEM 33, wherein the NDA+ related compound comprises nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.ITEM 35. The method, composition, or use of any one of ITEM 27 to ITEM 34, wherein the disease, condition, and / or symptom is linked to decreased NAD+.ITEM 36. The method, composition, or use of any one of ITEM 27 to ITEM 35, wherein the disease, condition, and / or symptom is one or more of diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and cancer.ITEM 37. A method of treating a disease, condition, and / or symptom associated with aging in a subject comprising administering to the subject a nicotinamide riboside proliposome composition, wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 38. A nicotinamide riboside proliposome composition for use in treating a disease, condition, and / or symptom associated with aging in a subject, wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 39. Use of a nicotinamide riboside proliposome composition in the manufacture of a medicament for treating a disease, condition, and / or symptom associated with aging in a subject, wherein the composition comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 40. A method of treating a disease, condition, and / or symptom associated with aging in a subject comprising administering to the subject a proliposome composition, wherein the proliposome comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 41. A proliposome composition for use in treating a disease, condition, and / or symptom associated with aging in a subject, wherein the proliposome comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 42. Use of a proliposome composition in the manufacture of a medicament for treating a disease, condition, and / or symptom associated with aging in a subject, wherein the composition comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 43. The method, composition, or use of any one of ITEM 40 to ITEM 42, wherein the NDA+ related compound comprises one or more of nicotinamide riboside chloride, a water soluble salt of nicotinamide riboside, nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR). ITEM 44. The method, composition, or use of ITEM 43, wherein the NDA+ related compound comprises nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.ITEM 45. The method, composition, or use of any one of ITEM 37 to ITEM 44, wherein the disease, condition, and / or symptom is linked to decreased NAD+.ITEM 46. The method, composition, or use of any one of ITEM 37 to ITEM 45, wherein the disease, condition, and / or symptom is one or more of diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and cancer.ITEM 47. A method of dietary management of a disease, condition, and / or symptom associated with aging in a subject comprising administering to the subject a nicotinamide riboside proliposome composition, wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 48. A nicotinamide riboside proliposome composition for use in dietary management of a disease, condition, and / or symptom associated with aging in a subject, wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 49. Use of a nicotinamide riboside proliposome composition in the manufacture of a medicament for dietary management of a disease, condition, and / or symptom associated with aging in a subject, wherein the composition comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 50. A method of dietary management of a disease, condition, and / or symptom associated with aging in a subject comprising administering to the subject a proliposome composition, wherein the proliposome comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 51. A proliposome composition for use in dietary management of a disease, condition, and / or symptom associated with aging in a subject, wherein the proliposome comprises:(a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 52. Use of a proliposome composition in the manufacture of a medicament for dietary management of a disease, condition, and / or symptom associated with aging in a subject, wherein the composition comprises: (a) about 40% to about 70% a NDA+ related compound by weight based on the total weight of the composition; (b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.ITEM 53. The method, composition, or use of any one of ITEM 50 to ITEM 52, wherein the NDA+ related compound comprises one or more of nicotinamide riboside chloride, a water soluble salt of nicotinamide riboside, nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR). ITEM 54. The method, composition, or use of ITEM 53, wherein the NDA+ related compound comprises nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.ITEM 55. The method, composition, or use of any one of ITEM 47 to ITEM 54, wherein the disease, condition, and / or symptom is linked to decreased NAD+.ITEM 56. The method, composition, or use of any one of ITEM 47 to ITEM 55, wherein the disease, condition, and / or symptom is one or more of diabetes, being overweight, obesity, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and cancer.ITEM 57. The method, composition, or use of any one of ITEM 1 to ITEM 56, wherein the composition comprises no more than about 2% organic solvent by weight based on the total weight of the composition. ITEM 58. The method, composition, or use of any one of ITEM 1 to ITEM 6, ITEM 15 to ITEM 19, ITEM 25 to ITEM 29, ITEM 35 to ITEM 39, ITEM 45 to ITEM 49, and ITEM 55 to ITEM 57, wherein the composition comprises one or more of the following:(a) about 47% to about 64% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.8% to about 6.2% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 30% to about 41 % dispersant by weight based on the total weight of the composition; and (d) about 1.6% to about 2.2% excipient by weight based on the total weight of the composition.ITEM 59. The method, composition, or use of any one of ITEM 1 to ITEM 6, ITEM 15 to ITEM 19, ITEM 25 to ITEM 29, ITEM 35 to ITEM 39, ITEM 45 to ITEM 49, and ITEM 55 to ITEM 58, wherein the composition comprises:(a) about 47% to about 64% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.8% to about 6.2% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 30% to about 41 % dispersant by weight based on the total weight of the composition; and (d) about 1.6% to about 2.2% excipient by weight based on the total weight of the composition.ITEM 60. The method, composition, or use of any one of ITEM 1 to ITEM 6, ITEM 15 to ITEM 19, ITEM 25 to ITEM 29, ITEM 35 to ITEM 39, ITEM 45 to ITEM 49, and ITEM 55 to ITEM 57, wherein the composition comprises one or more of the following:(a) about 52% to about 58% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 4.3% to about 5.6% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 34% to about 37% dispersant by weight based on the total weight of the composition; and (d) about 1.8% to about 2.0% excipient by weight based on the total weight of the composition.ITEM 61. The method, composition, or use of any one of ITEM 1 to ITEM 6, ITEM 15 to ITEM 19, ITEM 25 to ITEM 29, ITEM 35 to ITEM 39, ITEM 45 to ITEM 49, and ITEM 55 to ITEM 57, wherein the comprises: (a) about 52% to about 58% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 4.3% to about 5.6% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 34% to about 37% dispersant by weight based on the total weight of the composition; and (d) about 1.8% to about 2.0% excipient by weight based on the total weight of the composition.ITEM 62. The method, composition, or use of any one of ITEM 7 to ITEM 16, ITEM 20 to ITEM 26, ITEM 30 to ITEM 36, ITEM 40 to ITEM 46, and ITEM 50 to ITEM 57, wherein the composition comprises one or more of the following:(a) about 47% to about 64% the NDA+ related compound by weight based on the total weight of the composition;(b) about 3.8% to about 6.2% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 30% to about 41 % dispersant by weight based on the total weight of the composition; and (d) about 1.6% to about 2.2% excipient by weight based on the total weight of the composition.ITEM 63. The method, composition, or use of any one of ITEM 7 to ITEM 16, ITEM 20 to ITEM 26, ITEM 30 to ITEM 36, ITEM 40 to ITEM 46, and ITEM 50 to ITEM 57, wherein the composition comprises:(a) about 47% to about 64% the NDA+ related compound by weight based on the total weight of the composition;(b) about 3.8% to about 6.2% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 30% to about 41 % dispersant by weight based on the total weight of the composition; and (d) about 1.6% to about 2.2% excipient by weight based on the total weight of the composition.ITEM 64. The method, composition, or use of any one of ITEM 7 to ITEM 16, ITEM 20 to ITEM 26, ITEM 30 to ITEM 36, ITEM 40 to ITEM 46, and ITEM 50 to ITEM 57, wherein the composition comprises one or more of the following:(a) about 52% to about 58% the NDA+ related compound by weight based on the total weight of the composition;(b) about 4.3% to about 5.6% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 34% to about 37% dispersant by weight based on the total weight of the composition; and (d) about 1.8% to about 2.0% excipient by weight based on the total weight of the composition.ITEM 65. The method, composition, or use of any one of ITEM 7 to ITEM 16, ITEM 20 to ITEM 26, ITEM 30 to ITEM 36, ITEM 40 to ITEM 46, and ITEM 50 to ITEM 57, wherein the comprises:(a) about 52% to about 58% the NDA+ related compound by weight based on the total weight of the composition;(b) about 4.3% to about 5.6% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 34% to about 37% dispersant by weight based on the total weight of the composition; and (d) about 1.8% to about 2.0% excipient by weight based on the total weight of the composition.ITEM 66. The method, composition, or use of any one of ITEM 57 to ITEM 65, wherein the composition comprises 0.5% to about 2.0 % organic solvent by weight based on the total weight of the composition.ITEM 67. The method, composition, or use of any one of ITEM 57 to ITEM 66, wherein the composition comprises no more than about 1.5% organic solvent by weight based on the total weight of the composition. ITEM 68. The method, composition, or use of any one of ITEM 57 to ITEM 67, wherein the composition comprises about 0.5% to about 1.5% organic solvent by weight based on the total weight of the composition. ITEM 69. The method, composition, or use of any one of ITEM 57 to ITEM 68, wherein the organic solvent is ethanol.ITEM 70. The method, composition, or use of any one of ITEM 57 to ITEM 69, wherein the lipid system comprises about 65% to about 85% phospholipid by weight based on the total weight of the lipid system.ITEM 71. The method, composition, or use of any one of ITEM 57 to ITEM 70, wherein the lipid system comprises about 70% to about 80% phospholipid by weight based on the total weight of the lipid system.ITEM 72. The method, composition, or use of any one of ITEM 1 to ITEM 71, wherein the phospholipid comprises:(a) at least about 70% to about 97% phosphatidylcholine (PC) by weight based on the total weight of the phospholipid;(b) about 3.0% to about 5.0% lysophosphatidylcholine (LPC) by weight based on the total weight of the phospholipid; and(c) about 0.5% to about 0.8% phosphotidylethanolamine (PE) by weight based on the total weight of the phospholipid.ITEM 73. The method, composition, or use of any one of ITEM 1 to ITEM 72, wherein the phospholipid comprises:(a) at least about 80% to about 97% PC by weight based on the total weight of the phospholipid;(b) about 3.4% to about 4.6% LPC by weight based on the total weight of the phospholipid; and(c) about 0.55% to about 0.75% PE by weight based on the total weight of the phospholipid.ITEM 74. The method, composition, or use of any one of ITEM 1 to ITEM 73, wherein the phospholipid comprises:(a) at least about 90% to about 97% PC by weight based on the total weight of the phospholipid;(b) about 3.8% to about 4.2% LPC by weight based on the total weight of the phospholipid; and(c) about 0.6% to about 0.7% PE by weight based on the total weight of the phospholipid.ITEM 75. The method, composition, or use of any one of ITEM 1 to ITEM 74, wherein the lipid system is substantially free of phosphatidic acid (PA) and / or phosphatidylinositol (PI).ITEM 76. The method, composition, or use of any one of ITEM 1 to ITEM 75, wherein the lipid system comprises no more than 0.1% PA by weight based on the total amount of lipid system and / or no more than 0.1% PI by weight based on the total amount of the lipid system.ITEM 77. The method, composition, or use of any one of ITEM 1 to ITEM 76, wherein the lipid system comprises no more than 0.01% PA by weight based on the total amount of lipid system and / or no more than 0.01% PI by weight based on the total amount of the lipid system.ITEM 78. The method, composition, or use of any one of ITEM 1 to ITEM 77, wherein the lipid system comprises no more than 0.001% PA by weight based on the total amount of lipid system and / or no more than 0.001 % PI by weight based on the total amount of the lipid system.ITEM 79. The method, composition, or use of any one of ITEM 1 to ITEM 78, wherein the lipid system comprises lecithin, wherein the lecithin comprises from at least about 80% lipid to at least about 95% lipid by weight based on the total weight of the lecithin.ITEM 80. The method, composition, or use of any one of ITEM 1 to ITEM 79, wherein the lipid system comprises lecithin, wherein the lecithin comprises at least about 80% lipid by weight based on the total weight of the lecithin.ITEM 81. The method, composition, or use of any one of ITEM 1 to ITEM 80, wherein the lipid system comprises lecithin, wherein the lecithin comprises at least about 90% lipid by weight based on the total weight of the lecithin.ITEM 82. The method, composition, or use of any one of ITEM 1 to ITEM 81, wherein the lipid system comprises lecithin, wherein the lecithin comprises at least about 95% lipid by weight based on the total weight of the lecithin.ITEM 83. The method, composition, or use of any one of ITEM 1 to ITEM 82, wherein the lipid system comprises deoiled lecithin.ITEM 84. The method, composition, or use of any one of ITEM 1 to ITEM 82, wherein the lipid system consists essentially of deoiled lecithin.ITEM 85. The method, composition, or use of any one of ITEM 1 to ITEM 84, wherein the deoiled lecithin from one or more of sunflower deoiled lecithin, canola deoiled lecithin, rapeseed deoiled lecithin, and soy deoiled lecithin.ITEM 86. The method, composition, or use of any one of ITEM 1 to ITEM 85, wherein the lipid system consists essentially of deoiled lecithin enriched in PC.ITEM 87. The method, composition, or use of any one of ITEM 83 to ITEM 86, wherein the deoiled lecithin comprises about 70% to about 80% phospholipid by weight based on the total weight of the deoiled lecithin, and about 69% to about 77% PC by weight based on the total weight of the phospholipid comprised in the deoiled lecithin.ITEM 88. The method, composition, or use of any one of ITEM 83 to ITEM 87, wherein the deoiled lecithin is sunflower deoiled lecithin.ITEM 89. The method, composition, or use of any one of ITEM 1 to ITEM 88, wherein the lipid system consists essentially of sunflower deoiled lecithin.ITEM 90. The method, composition, or use of any one of ITEM 88 or ITEM 89, wherein the sunflower deoiled lecithin comprises about 70% to about 80% phospholipid by weight based on the total weight of the sunflower deoiled lecithin.ITEM 91. The method, composition, or use of ITEM 90, wherein the sunflower deoiled lecithin consists essentially of(a) about 69% to about 77% PC by weight based on the total weight of the phospholipid comprised in the sunflower lecithin;(b) about 2.9% to about 3.5% LPC by weight based on the total weight of the phospholipid comprised in the sunflower lecithin; and(c) about 0.45% to about 0.55% PE by weight based on the total weight of the phospholipid comprised in the sunflower lecithin.ITEM 92. The method, composition, or use of any one of ITEM 1 to ITEM 91, wherein the dispersant is one or more of lactose, maltodextrin, mannitol, sorbitol, sucrose, trehalose, and xylitol.ITEM 93. The method, composition, or use of any one of ITEM 1 to ITEM 92, wherein the dispersant is maltodextrin.ITEM 94. The method, composition, or use of any one of ITEM 1 to ITEM 93, wherein the excipient is one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, and magnesium stearate.ITEM 95. The method, composition, or use of any one of ITEM 1 to ITEM 94, wherein the excipient is colloidal silica (anhydrous).ITEM 96. A method, composition, or use as described in any one of ITEM 1 to ITEM 6, ITEM 15 to ITEM 19, ITEM 25 to ITEM 29, ITEM 35 to ITEM 39, ITEM 45 to ITEM 49, ITEM 55 to ITEM 61 , and ITEM 66 to ITEM 95, wherein nicotinamide riboside chloride is replaced with an alternative water-soluble salt of nicotinamide riboside.ITEM 97. The method, composition, or use of ITEM 96, wherein the alternative water-soluble salt of nicotinamide riboside is nicotinamide malate and / or nicotinamide tartrate.ITEM 98. The method, composition, or use of ITEM 96, wherein the alternative water-soluble salt of nicotinamide riboside is nicotinamide riboside chloride in combination with nicotinamide malate and / or nicotinamide tartrate.ITEM 99. The method, composition, or use of any one of ITEM 1 to ITEM 98, wherein the composition has a mean particle size of no more than about 400 pm, no more than about 350 pm, or no more than about 300 pm.ITEM 100. The method, composition, or use of any one of ITEM 1 to ITEM 99, wherein the composition has a mean particle size of no more than about 300 pm.ITEM 101. The method, composition, or use of ITEM 100, wherein Dio is less than about 100 pm, D50 is less than about 200 pm, and D90 is less than about 400 pm.ITEM 102. The method, composition, or use of any one of ITEM 99 to ITEM 101 , wherein the mean particle size is determined by laser diffraction.ITEM 103. The method, composition, or use of any one of ITEM 1 to ITEM 102, wherein when 100 mg of the composition is mixed with 100 ml of water, the liposomal particle size (Z-average (d.nm)) is less than about400 nm, less than about 350 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, or less than about 50 nm.ITEM 104. The method, composition, or use of any one of ITEM 1 to ITEM 103, wherein when 100 mg of the composition is mixed with 100 ml of water, the liposomal particle size (Z-average (d.nm)) is less than about 300 nm.ITEM 105. The method, composition, or use of ITEM 103 or ITEM 104, wherein the liposomal particle size (Z-average (d.nm)) is determined by Dynamic Light Scattering (DLS).ITEM 106. The method, composition, or use of ITEM 105, wherein the DLS is Multi-Angle Dynamic Light Scattering.ITEM 107. The method, composition, or use of any one of ITEM 1 to ITEM 106, wherein the composition comprises nicotinamide riboside chloride, and wherein the subject is administered a daily dose of the composition in an amount to deliver at least about 250 mg nicotinamide riboside.ITEM 108. The method, composition, or use of any one of ITEM 1 to ITEM 107, wherein the composition comprises nicotinamide riboside chloride, and wherein the subject is administered a daily dose of the composition in an amount to deliver about 250 mg to about 1000 mg nicotinamide riboside.ITEM 109. The method, composition, or use of ITEM 107 or ITEM 108, wherein the daily dose is delivered in one administration per day.ITEM 110. The method, composition, or use of ITEM 107 or ITEM 108, wherein the daily dose is divided into two, three, or four administrations per day, wherein the total amount administered is equal to the daily dose. ITEM 111. The method or composition of any one of ITEM 1, ITEM 2, ITEM 4, ITEM 5, ITEM 7, ITEM 8, ITEM 10, ITEM 11, ITEM 13 to ITEM 18, ITEM 20, ITEM 21, ITEM 23 to ITEM 28, ITEM 30, ITEM 31, ITEM 33 to ITEM 38, ITEM 40, ITEM 41, ITEM 45 to ITEM 48, ITEM 50, ITEM 51 and ITEM 53 to ITEM 110, wherein the composition is formulated for oral administration.ITEM 112. The use of any one of ITEM 3, ITEM 6, ITEM 9, ITEM 12 to ITEM 16, ITEM 19 to ITEM 26, ITEM 29 to ITEM 36, ITEM 39 to ITEM 46, ITEM 49, and ITEM 52 to ITEM 110, wherein the medicament is formulated for oral administration.ITEM 113. The method, composition, or use of ITEM 111 or ITEM 112, wherein the oral formulation comprises at least about 50% by weight of the composition based on the total weight of the oral formulation and no more than about 50% by weight formulating excipient based on the total weight of the oral formulation.ITEM 114. The method, composition, or use of ITEM 113, wherein the formulating excipient is one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, magnesium stearate, dicalcium phosphate dihydrate, hypromellose, and microcrystalline cellulose.ITEM 115. The method, composition, or use of any one of ITEM 111 to ITEM 114, wherein the oral administration formulation allows the formation of a liposome in the mouth.ITEM 116. The method, composition, or use of ITEM 115, wherein the oral administration formulation is a chewable tablet or orally disintegrating tablet.ITEM 117. The method, composition, or use of any one of ITEM 111 to ITEM 114, wherein the oral administration formulation allows the formation of a liposome in the stomach.ITEM 118. The method, composition, or use of ITEM 117, wherein the oral administration formulation is in a capsule or is an enterically coated tablet.ITEM 119. The method, composition, or use of any one of ITEM 110 to ITEM 114, wherein the oral administration formulation is in a capsule.ITEM 120. The method, composition, or use of any one of ITEM 1 to ITEM 119, wherein the composition, medicament, or formulation is shelf stable for at least about 3 months at a temperature of about 20°C to about 25°C.ITEM 121. The method, composition, or use of any one of ITEM 1 to ITEM 120, wherein the composition, medicament, or formulation is shelf stable for at least about 6 months at a temperature of about 20°C to about 25°C.ITEM 122. The method, composition, or use of any one of ITEM 1 to ITEM 121, wherein the composition, medicament, or formulation is shelf stable for at least about 12 months at a temperature of about 20°C to about 25°C.ITEM 123. The method, composition, or use of any one of ITEM 120 to ITEM 122, wherein the composition comprises nicotinamide riboside chloride and the shelf stability of the composition, medicament, or formulation is determined on the basis of one or more of:(a) color;(b) appearance:(c) solubility in water;(d) loss on drying;(e) particle size;(f) liposomal particle size (Z-average (d.nm)); and(g) identity of nicotinamide riboside;after storage of the composition, medicament, or formulation a temperature of about 20°C to about 25°C in comparison to the composition, medicament, or formulation when prepared.ITEM 124. A method of preparing a proliposome composition, comprising(a) preparing a first mixture of an organic solvent and a lipid system as herein described;(b) spraying the first mixture onto an active ingredient to form a second mixture, wherein the spraying is airless spraying;(c) adding to the second mixture a dispersant to form a third mixture; and(d) adding to the third mixture an excipient to form a final mixture.ITEM 125. The method of ITEM 124, wherein the method is carried out at about 20°C to about 25°C. ITEM 126. The method of ITEM 124 or ITEM 125, wherein the active ingredient comprises two or more active ingredients; the two or more the active ingredients are mixed prior to (b) to form a premix of activeingredients; and (b) is spraying the first mixture onto a premix of active ingredients to form the second mixture, wherein the spaying is airless spraying.ITEM 127. The method of any one of ITEM 124 to ITEM 126, wherein no additional liquid is added.ITEM 128. A method of preparing a proliposome composition, wherein the method comprises:(a) preparing a first mixture of an organic solvent and a lipid system as herein described;(a’) adding an active ingredient into a high shear mixer;(b) spraying the first mixture onto the active ingredient to form a second mixture, wherein the spraying is airless spraying;(b’) mixing the second mixture in the high shear mixer;(c) adding to the second mixture a dispersant to form a third mixture;(c’) mixing the third mixture in the high shear mixer;(d) adding to the third mixture an excipient to form a final mixture; and(d’) mixing the final mixture in the high shear mixer;wherein(i) the method is carried out at about 20°C to about 25°C; and(ii) the mixing in each of (b’), (c’), and (d’) is no more than about 10 minutes.ITEM 129. The method of ITEM 128, wherein the mixing of each of (b’), (c’), and (d’) is no more than about 5 minutes.ITEM 130. The method of any one of ITEM 124 to ITEM 129, wherein the first mixture has a ratio of the lipid system to the organic solvent of about 5:1 to 2.2: 1.ITEM 131. The method of any one of ITEM 124 to ITEM 130, wherein the first mixture has a ratio of the lipid system to the organic solvent of about 4.5: 1 to 2.8:1.ITEM 132. The method of any one of ITEM 124 to ITEM 131, wherein the first mixture has a ratio of the lipid system to the organic solvent of about 4.2:1 to 3.2:1.ITEM 133. The method of any one of ITEM 124 to ITEM 132, wherein the first mixture has a ratio of the lipid system to the organic solvent of about 4: 1.ITEM 134. The method of any one of ITEM 128 to ITEM 133, wherein the active ingredient comprises two or more active ingredients; the two or more the active ingredients are added into the high shear mixture in (a’) and mixed prior to form a premix of active ingredients; and (b) is spraying the first mixture onto the premix of active ingredients to form the second mixture, wherein the spraying is airless spraying.ITEM 135. The method of ITEM 134, wherein the mixing of the two or more active ingredients is no more than about 10 minutes or no more than about 5 minutes.ITEM 136. The method of any one of ITEM 124 to ITEM 135, wherein the active ingredient comprises a hydrophilic active ingredient.ITEM 137. The method of any one of ITEM 124 to ITEM 136, wherein the active ingredient comprises a lipophilic active ingredient.ITEM 138. The method of any one of ITEM 124 to ITEM 137, wherein the active ingredient comprises a water-soluble salt of nicotinamide riboside.ITEM 139. The method of ITEM 138, wherein the active ingredient consists essentially of a water-soluble salt of nicotinamide riboside.ITEM 140. The method of ITEM 138, wherein the active ingredient consists of a water-soluble salt of nicotinamide riboside.ITEM 141. The method of any one of ITEM 124 to ITEM 140, wherein the active ingredient is two or more water soluble salt of nicotinamide riboside.ITEM 142. The method of ITEM 141, wherein the two or more water soluble salts of nicotinamide riboside are nicotinamide riboside chloride, nicotinamide riboside malate, and / or nicotinamide riboside tartrate.ITEM 143. The method of any one of ITEM 124 to ITEM 133, wherein the active ingredient is a nicotinamide riboside chloride.ITEM 144. The method of any one of ITEM 124 to ITEM 135, wherein the active ingredient comprises one or more NAD+ related compounds.ITEM 145. The method, composition, or use of any one of ITEM 124 to ITEM 144, wherein the NDA+ related compound comprises one or more of nicotinamide riboside chloride, a water soluble salt of nicotinamide riboside, nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR). ITEM 146. The method, composition, or use of ITEM 145, wherein the NDA+ related compound comprises nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.ITEM 147. The method of any one of ITEM 124 to ITEM 146, wherein the dispersant is one or more of lactose, maltodextrin, mannitol, sorbitol, sucrose, trehalose, and xylitol.ITEM 148. The method of any one of ITEM 124 to ITEM 147, wherein the dispersant is maltodextrin. ITEM 149. The method of any one of ITEM 124 to ITEM 148, wherein the excipient is one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, and magnesium stearate.ITEM 150. The method of any one of ITEM 124 to ITEM 149, wherein the excipient is colloidal silica (anhydrous).ITEM 151. The method of any one of ITEM 124 to ITEM 150, wherein the organic solvent is ethanol. ITEM 152. The proliposome composition obtained by the method of any one of ITEM 124 to ITEM 151. ITEM 153. The proliposome composition obtainable by the method of any one of ITEM 124 to ITEM 151. ITEM 154. The proliposome composition of ITEM 152 or ITEM 153, wherein the proliposome composition comprises(a) about 40% to about 70%, about 47% to about 64%, or about 52% to about 58%, of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.3% to about 6.7%, about 3.8% to about 6.2%, or about 4.3% to about 5.6%, of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45%, about 30% to about 41%, or about 34% to about 37%, dispersant by weight based on the total weight of the composition;(d) about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition; and(e) no more than about 2%, about 0.5% to about 2%, no more than about 1.5%, or about 0.5% to about 1.5%, organic solvent based on the total weight of the composition.ITEM 155. A proliposome composition comprising(a) about 40% to about 70% of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition;(d) about 1.4% to about 2.4%excipient by weight based on the total weight of the composition; and(e) no more than about 2% organic solvent based on the total weight of the composition.ITEM 156. The composition of ITEM 154 or ITEM 155, wherein the composition comprises one or more of the following:(a) about 47% to about 64% of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.8% to about 6.2% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 30% to about 41 % dispersant by weight based on the total weight of the composition;(d) about 1.6% to about 2.2% excipient by weight based on the total weight of the composition; and(e) no more than about 2% or about 0.5% to about 2% organic solvent based on the total weight of the composition.ITEM 157. The composition of any one of ITEM 154 to ITEM 156, wherein the composition comprises: (a) about 47% to about 64% of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.8% to about 6.2% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 30% to about 41 % dispersant by weight based on the total weight of the composition;(d) about 1.6% to about 2.2% excipient by weight based on the total weight of the composition; and(e) about 0.5% to about 2% organic solvent based on the total weight of the composition.ITEM 158. The composition of any one of ITEM 154 to ITEM 157, wherein the composition comprises one or more of the following:(a) about 52% to about 58% of one or more active ingredients by weight based on the total weight of the composition;(b) about 4.3% to about 5.6% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 34% to about 37% dispersant by weight based on the total weight of the composition;(d) about 1.8% to about 2.0% excipient by weight based on the total weight of the composition; and(e) no more than about 1.5% or about 0.5% to 1.5% organic solvent based on the total weight of the composition.ITEM 159. The composition any one of ITEM 154 to ITEM 158, wherein the composition consists essentially of:(a) about 52% to about 58% of one or more active ingredients by weight based on the total weight of the composition;(b) about 4.3% to about 5.6% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 34% to about 37% dispersant by weight based on the total weight of the composition;(d) about 1.8% to about 2.0% excipient by weight based on the total weight of the composition; and(e) about 0.5% to about 1.5% organic solvent by weight based on the total weight of the composition.ITEM 160. The composition of any one of ITEM 154 to ITEM 159, wherein the organic solvent is ethanol. ITEM 161. The composition of any one of ITEM 154 to ITEM 160, wherein the lipid system comprises about 65% to about 85% phospholipid by weight based on the total weight of the lipid system.ITEM 162. The composition of any one of ITEM 154 to ITEM 161, wherein the lipid system comprises about 70% to about 80% phospholipid by weight based on the total weight of the lipid system.ITEM 163. The composition of any one of ITEM 154 to ITEM 162, wherein the phospholipid comprises: (a) at least about 70% to about 97% PC by weight based on the total weight of the phospholipid;(b) about 3.0% to about 5.0% LPC by weight based on the total weight of the phospholipid; and(c) about 0.5% to about 0.8% PE by weight based on the total weight of the phospholipid.ITEM 164. The composition of any one of ITEM 154 to ITEM 163, wherein the phospholipid comprises: (a) at least about 80% to about 97% PC by weight based on the total weight of the phospholipid;(b) about 3.4% to about 4.6% LPC by weight based on the total weight of the phospholipid; and(c) about 0.55% to about 0.75% PE by weight based on the total weight of the phospholipid.ITEM 165. The composition of any one of ITEM 154 to ITEM 164, wherein the phospholipid comprises: (a) at least about 90% to about 97% PC by weight based on the total weight of the phospholipid;(b) about 3.8% to about 4.2% LPC by weight based on the total weight of the phospholipid; and (c) about 0.6% to about 0.7% PE by weight based on the total weight of the phospholipid.ITEM 166. The composition of any one of ITEM 154 to ITEM 165, wherein the lipid system is substantially free of phosphatidic acid (PA) and / or phosphatidylinositol (PI).ITEM 167. The composition of any one of ITEM 154 to ITEM 166, wherein the lipid system comprises no more than 0.1% PA by weight based on the total amount of lipid system and / or no more than 0.1% PI by weight based on the total amount of the lipid system.ITEM 168. The composition of any one of ITEM 154 to ITEM 167, wherein the lipid system comprises no more than 0.01 % PA by weight based on the total amount of lipid system and / or no more than 0.01 % PI by weight based on the total amount of the lipid system.ITEM 169. The composition of any one of ITEM 154 to ITEM 168, wherein the lipid system comprises no more than 0.001% PA by weight based on the total weight of phospholipid and / or no more than 0.001% PI by weight based on the total weight of the phospholipid.ITEM 170. The composition of any one of ITEM 154 to ITEM 169, wherein the lipid system comprises lecithin, wherein the lecithin comprises from at least about 80% lipid to at least about 95% lipid by weight based on the total weight of the lecithinITEM 171. The composition of any one of ITEM 154 to ITEM 170, wherein the lipid system comprises lecithin, wherein the lecithin comprises at least about 80% lipid by weight based on the total weight of the lecithin. ITEM 172. The composition of any one of ITEM 154 to ITEM 171, wherein the lipid system comprises lecithin, wherein the lecithin comprises at least about 90% lipid by weight based on the total weight of the lecithin. ITEM 173. The composition of any one of ITEM 154 to ITEM 172, wherein the lipid system comprises lecithin, wherein the lecithin comprises at least about 95% lipid by weight based on the total weight of the lecithin. ITEM 174. The composition of any one of ITEM 154 to ITEM 173, wherein the lipid system comprises deoiled lecithin.ITEM 175. The composition of any one of ITEM 154 to ITEM 174, wherein the lipid system consists essentially of deoiled lecithin.ITEM 176. The composition of any one of ITEM 154 to ITEM 175, wherein the lipid system consists essentially of deoiled lecithin enriched in PC.ITEM 177. The composition of any one of ITEM 154 to ITEM 176, wherein the deoiled lecithin comprises about 70% to about 80% phospholipid by weight based on the total weight of the deoiled lecithin, and about 69% to about 77% PC by weight based on the total weight of the phospholipid comprised in the deoiled lecithin. ITEM 178. The composition of any one of ITEM 154 to ITEM 177, wherein the deoiled lecithin is one or more of sunflower deoiled lecithin, canola deoiled lecithin, rapeseed deoiled lecithin, and soy deoiled lecithin. ITEM 179. The composition of any one of ITEM 154 to ITEM 178, wherein the deoiled lecithin consist essentially of sunflower deoiled lecithin.ITEM 180. The composition of any one of ITEM 154 to ITEM 179, wherein the lipid system consists essentially of sunflower deoiled lecithin.ITEM 181. The composition of ITEM 179 or ITEM 180, wherein the sunflower deoiled lecithin comprises about 70% to about 80% phospholipid by weight based on the total weight of the sunflower deoiled lecithin. ITEM 182. The composition of ITEM 181 , wherein the sunflower deoiled lecithin consists essentially of (a) about 69% to about 77% PC by weight based on the total weight of the phospholipid comprised in the sunflower lecithin;(b) about 2.9% to about 3.5% LPC by weight based on the total weight of the phospholipid comprised in the sunflower lecithin; and(c) about 0.45% to about 0.55% PE by weight based on the total weight of the phospholipid comprised in the sunflower lecithin.ITEM 183. The composition of any one of ITEM 154 to ITEM 182, wherein the dispersant is one or more of lactose, maltodextrin, mannitol, sorbitol, sucrose, trehalose, and xylitol.ITEM 184. The composition of any one of ITEM 154 to ITEM 183, wherein the dispersant is maltodextrin. ITEM 185. The composition of any one of ITEM 154 to ITEM 184, wherein the excipient is one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, and magnesium stearate.ITEM 186. The composition of any one of ITEM 154 to ITEM 185, wherein the excipient is colloidal silica (anhydrous).ITEM 187. The composition of any one of ITEM 154 to ITEM 186, wherein the composition has a mean particle size of no more than about 400 pm, no more than about 350 pm, or no more than about 300 pm. ITEM 188. The composition of any one of ITEM 154 to ITEM 187, wherein the composition has a mean particle size of no more than about 300 pm.ITEM 189. The composition of ITEM 188, wherein Dio is less than about 100 pm, D50 is less than about 200 pm, and D90 is less than about 400 pm.ITEM 190. The composition of any one of ITEM 187 to ITEM 189, wherein the mean particle size is determined by laser diffraction.ITEM 191. The composition of any one of ITEM 154 to ITEM 190, wherein when 100 mg of the composition is mixed with 100 ml of water, the liposomal particle size (Z-average (d.nm)) is less than about 400 nm, less than about 350 nm, or less than about 300 nm, less than about 200 nm, less than about 100 nm, or less than about 50 nm.ITEM 192. The composition of any one of ITEM 154 to ITEM 191, wherein when 100 mg of the composition is mixed with 100 ml of water, the liposomal particle size (Z-average (d.nm)) is less than about 300 nm.ITEM 193. The composition of ITEM 191 or ITEM 192, wherein the liposomal particle size (Z-average (d.nm)) is determined by Dynamic Light Scattering (DLS).ITEM 194. The composition of ITEM 193, wherein the DLS is Multi-Angle Dynamic Light Scattering.ITEM 195. The composition of any one of ITEM 154 to ITEM 194, wherein the composition has a shelf life of at least 3 months.ITEM 196. The composition of any one of ITEM 154 to ITEM 195, wherein the composition has a shelf life of at least 6 months.ITEM 197. The composition of any one of ITEM 154 to ITEM 196, wherein the composition has a shelf life of at least 12 months.ITEM 198. The composition of any one of Items 157 to ITEM 197, wherein shelf stability of the composition is determined on the basis of one or more of:(a) color;(b) appearance;(c) solubility in water;(d) loss on drying;(e) particle size;(f) liposomal particle size (Z-average (d.nm)); and(g) identity of active ingredient;after storage of the composition, medicament, or formulation a temperature of about 20°C to about 25°C in comparison to the composition, medicament, or formulation when prepared.ITEM 199. The composition of any one of ITEM 154 to ITEM 198, wherein the active ingredient comprises a hydrophilic active ingredient.ITEM 200. The composition of any one of ITEM 154 to ITEM 199, wherein the active ingredient comprises lipophilic active ingredient.ITEM 201. The composition of any one of ITEM 154 to ITEM 200, wherein the active ingredient is nicotinamide riboside chloride, nicotinamide riboside malate, and / or nicotinamide riboside tartrate.ITEM 202. The composition of any one of ITEM 154 to ITEM 201, wherein the active ingredient is nicotinamide riboside chloride.ITEM 203. The composition of any one of ITEM 154 to ITEM 198, wherein the active ingredient comprises one or more NAD+ related compounds.ITEM 204. The composition of ITEM 203, wherein the NDA+ related compound comprises one or more of nicotinamide riboside chloride, a water soluble salt of nicotinamide riboside, nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR).ITEM 205. The composition of ITEM 203, wherein the NDA+ related compound comprises nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.ITEM 206. The composition of any one of ITEM 154 to ITEM 205, wherein the composition is formulated for oral administration.ITEM 207. The composition of ITEM 206, wherein the oral administration formulation allows the formation of a liposome in the mouth.ITEM 208. The composition of ITEM 207, wherein the oral administration formulation is a chewable tablet or orally disintegrating tablet.ITEM 209. The composition of ITEM 206, wherein the oral administration formulation allows the formation of a liposome in the stomach.ITEM 210. The composition of ITEM 209, wherein the oral administration formulation is in a capsule or is an enterically coated tablet.ITEM 211. The composition of ITEM 206 to ITEM 210, wherein the oral formulation comprises at least about 50% by weight of the composition based on the total weight of the oral formulation and no more than about 50% by weight formulating excipient based on the total weight of the oral formulation.ITEM 212. The method, composition, or use of ITEM 211, wherein the formulating excipient is one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, magnesium stearate, dicalcium phosphate dihydrate, hypromellose, and microcrystalline cellulose.ITEM 213. The composition of any one of ITEM 206 to ITEM 212, wherein the active ingredient is nicotinamide riboside chloride and the oral administration formulation comprises the equivalent of at least about 250 mg nicotinamide riboside.ITEM 214. The composition of any one of ITEM 206 to ITEM 212, wherein the active ingredient is nicotinamide riboside chloride and the oral administration formulation comprises the equivalent of about 250 mg to about 1000 mg nicotinamide riboside.ITEM 215. The composition of any one of ITEM 154 to ITEM 214 for use as a medicament.EXAMPLES

[0178] Example 1: Exemplary Method for Preparing a Nicotinamide Riboside Proliposome Composition

[0179] A nicotinamide riboside proliposome composition may be prepared by following procedure, which is carried out at about 20°C to about 25°C:Step 1 : Preparing a First Mixture, which is a mixture of a lipid system in an organic solvent, where:the lipid system is a sunflower lecithin that typically has about 70%-80% phospholipid by weight based on the total weight of the lecithin, where the phospholipid is typically about 69% to about 77% phosphatidylcholine (PC) by weight based on the total weight of the lecithin, about 2.9% to about 3.3% lysophosphatidylcholine (LPC) by weight based on the total weight of the lecithin, about 0.45% to about 0.55% phosphatidylethanolamine (PE) by weight based on the total weight of the lecithin, less than 0.001% phosphatidic acid (PA) by weight based on the total weight of the lecithin, and less than 0.001% phosphatidylinositol (PI) by weight based on the total weight of the lecithin;the organic solvent is ethanol;the ratio of lecithin to ethanol is about 4: 1.Step 2: Adding nicotinamide riboside chloride into a high shear mixer, wherein the high shear mixer is set to 100 rpm and the blade speed is set to 2000 rpm.Step 3: Starting the high shear mixer.Step 4: Spraying the First Mixture by airless spraying onto the nicotinamide riboside chloride while mixing in the high shear mixer for about 5 minutes to form a Second Mixture.Step 5: Stopping the high shear mixer.Step 6. Adding a dispersant (maltodextrin) into the high shear mixer and stating the high shear mixer and mixing for about 5 minutes to form a Third Mixture.Step 7: Adding an excipient (colloidal silica (anhydrous)) into the high shear mixer and stating the high shear mixer and mixing for about 5 minutes to form a Final Mixture

[0180] Example 2: Preparation of a Nicotinamide Riboside Proliposome Composition

[0181] Batch 1: The general procedure outlined in Example 1 was followed to prepare the nicotinamide riboside proliposome composition. The nicotinamide riboside proliposome composition included the following ingredients in Table 2:Table 2 - Nicotinamide riboside proliposome compositionIngredient Kgnicotinamide riboside chloride 42.05maltodextrin 27.10lecithin:ethanol (4:1 ratio) 5.30colloidal silica (anhydrous) 1.46

[0182] During the preparation, the temperature was 21 ,5°C with 52% relative humidity.

[0183] The nicotinamide riboside chloride (42.05 kg) was dispensed into a high shear mixer, with the mixer speed set to 100 rpm and the blade speed set to 2,000 rpm. The mixer was started. 5.30 kg of a mixture of sunflower lecithin and ethanol in a ratio of 4:1 was sprayed (by airless spraying) onto the nicotinamide riboside chloride. The airless spraying was continued for about 5 minutes. Mixing was continued for an additional 5 minutes. The mixer was stopped, and maltodextrin (27.10 kg) was dispensed into the high shear mixer. The mixture was mixed for about 5 minutes. The mixer was stopped, and colloidal silica (anhydrous) (1.46 kg) was dispensed into the high shear mixer. The mixture was mixed for about 5 minutes. An off-white, powder was produced.

[0184] Additional batches were prepared by the same method as described for Batch 1 :Batch 2: Nicotinamide riboside chloride (42.10 kg), lecithimethanol (ratio 4:1) (5.30 kg), maltodextrin (27.02), colloidal silica (anhydrous) (1.47 kg). During the preparation, the temperature was 21 ,9°C with 62% relative humidity. An off-white powder, was produced.Batch 3: Nicotinamide riboside chloride (42.10 kg), I lecithimethanol (ratio 4:1) (5.30 kg), maltodextrin (27.32), colloidal silica (anhydrous) (1.453 kg). During the preparation, the temperature was 22.1°C with 60% relative humidity. An off-white, powder was produced.Batch 4: Nicotinamide riboside chloride (41.70 kg), lecithimethanol (ratio 4:1) (5.30 kg), maltodextrin (27.30), colloidal silica (anhydrous) (1.465 kg). During the preparation, the temperature was 22.4°C with 62% relative humidity. An off-white, powder was produced.

[0185] The sunflower lecithin used in batches 1 to 4 complied with the description in step 1 of Example 1.

[0186] The four batches were combined and analysed as follows:Appearance (visual inspection - off-white, powder) complied.Solubility (500 mg disperses as a colloidal solution in 250 ml water): complied.Loss on drying - Not More Than 5%: measured - 1.7%.Table 3 - Particle size (powder) by laser diffraction:Parameter MeasuredMean particle size < 300 pm 156.6 pmDio < 100 pm 51.4 pmD50 < 200 pm 120.3 pmD90 < 400 pm 280.6 pmLiposomal particle size, 100 mg powder dispersed in 100 ml water, (Z-average (d.nm) < 300 nm) by Multi-Angle Dynamic Light Scattering: measured 27 nm.Ethanol: 1.4% by weight based on the total weight of the composition. (Quantified by input)Colloidal silica anhydrous: 1.9% by weight based on the total weight of the composition. (Quantified by input) Active ingredient (nicotinamide riboside chloride - Not Less Than 500 mg / g): measured 532.5 mg / g.

[0187] Example 3: Bioavailability of Nicotinamide Riboside Proliposome Composition

[0188] The bioavailability of nicotinamide riboside was assessed by measuring NAD+ after administration of proliposome composition comprising nicotinamide riboside in the form of the chloride salt, nicotinamide riboside chloride, (at high and low concentration), a composition of nicotinaminde riboside chloride in water, and a composition of nicotinamide mononucleotide in water.

[0189] The nicotinamide riboside proliposome according to the following was prepared as in Table 4:Table 4 - nicotinamide riboside proliposome compositionIngredient Weight percent based on total weight of the compositionnicotinamide riboside chloride 55.3maltodextrin 35.8lecithin 5.6colloidal silica (anhydrous) 1.9Ethanol < 20190] The nicotinamide riboside proliposome formu ation was prepared at lab scale by preparing two smal batches that were combined. Each of the two small batches were prepared by the following protocol using the same amounts as follows: Nicotinamide riboside chloride (235.025 g) was dispensed into a mixing vessel. A mixture of sunflower lecithin and ethanol in ratio of 4: 1 (29.75 g) was added into the mixer and the mixture thoroughly mixed to coat the nicotinamide riboside chloride. Maltodextrin (152.15g) was dispensed into the mixer and mixed until the powder was homogeneous. Colloidal silica (anhydrous) (8.075g) was dispensed into the mixing vessel and mixed until the powder was homogenous. The sunflower lecithin used complied with the description in step 1 of Example 1. The two batches combined amount to a total of 850 g of the nicotinamide riboside proliposome composition.

[0191] Protocol As Administered: 110 C57BL / 6J mice aged 8 weeks were acclimatized for 3 days before the experiment began. On day 0, 10 mice were sacrificed, and their plasma and liver samples were collected to test NAD+ detection methods. The remaining 100 mice were randomly divided into five groups, with 20 mice in each group. The mice were administered by gavage for 14 consecutive days: the control group (CON) received water, the NR group received 261 mg / kg Nicotinamide Riboside Chloride (NR) (EffePharm), the NMN group received 300 mg / kg NMN (EffePharm), the LNR group received 522 mg / kg nicotinamide riboside in the form of a liposome prepared from the nicotinamide riboside proliposome composition lab scale batch described above , and the HNR group received 5220 mg / kg nicotinamide riboside in the form of a liposome prepared from the nicotinamide riboside proliposome composition lab scale batch described above. The solutions were prepared fresh daily. On day 8, 10 mice from each group were sacrificed, and their plasma and liver samples were collected for NAD+ detection. On day 15, the remaining 10 mice from each group were sacrificed, and their plasma and liver samples were collected for NAD+ detection.

[0192] Table 5 summarizes the experimental plan.NumberGroup Treatmentof miceCON 20 Administering water (pL) by gavage at a volume of 10 times the mouse's body weight (g)Prepare a 26.1 mg / mL NR solution and administer it by gavage at a volume of 10 times NR 20the mouse's body weightPrepare a 30 mg / mL NMN solution and administer it by gavage at a volume of 10 times NMN 20the mouse's body weightPrepare a 52.2 mg / mL NR solution from nicotinamide riboside proliposome composition LNR 20and administer it by gavage at a volume of 10 times the mouse's body weight Prepare a 522 mg / mL NR solution from nicotinamide riboside proliposome composition HNR 20and administer it by gavage at a volume of 10 times the mouse's body weight

[0193] NAD+ Detection: Coenzyme I, NAD(H), is widely present in animals, plants, microorganisms, and cultured cells. NAD+ serves as the primary hydrogen acceptor in glycolysis and the tricarboxylic acid (TCA) cycle. The generated NADH transfers electrons through the electron transport chain, delivering them to oxygen. During this process, ATP is synthesized, and a significant amount of reactive oxygen species (ROS) is produced, while NADH is regenerated into NAD+. The majority of oxidative reactions in the breakdown of the three major metabolic substances— carbohydrates, lipids, and proteins— are accomplished through this system. NAD+ is extracted from samples using an acidic extraction solution. The extracted NAD+can then be reduced to NADH by alcohol dehydrogenase. Subsequently, the NAD+ content is determined using the MTT reduction method.

[0194] Experimental Procedures (Liver and plasma NAD+ detection): NAD+ detection was performed after liver and plasma were collected on day 8 and day 15. Plasma NAD+ extraction: add 0.3mL of acidic extractant to 10OpL of plasma, boil at 100°C for 5min (cover tightly to prevent water loss); cool in an ice bath, centrifuge at 10000g for 10min at 4°C; take the supernatant to another new centrifuge tube, add an equal volume of alkaline extractant to neutralize, mix, centrifuge at 10000g for 10min at 4°C, take the supernatant, and place on ice for testing. Liver NAD+ extraction: add 0.5 mL of acidic extractant to 50 mg of liver, grind in an ice bath, boil at 100 degrees Celsius for 5 min (cover tightly to prevent water loss); cool in an ice bath, centrifuge at 10000g for 10 min at 4°C; take the supernatant to another new centrifuge tube, add an equal volume of alkaline extractant to neutralize, mix, centrifuge at 10000g for 10 min at 4°C, take the supernatant, and place on ice for testing.

[0195] The subsequent measurement steps were carried out according to the Coenzyme I NAD(H) Assay Kit (A114-1-1) of Nanjing Jiancheng Bioengineering Institute.

[0196] Changes in NAD+ content: The changes in plasma NAD+ content on day 8 and day 15 are shown in FIG. 1. The NR, NMN, LNR and HNR groups can all increase the NAD+ content in plasma, but the degree of increase is different, HNR>LNR>NMN>NR.

[0197] Table 6: The mean and standard error of plasma NAD+ content in each group of miceAverageGroup Day SEM(nmol / ml)CON 6.045 0.144NR 6.832 0.069NMN Day 8 7.943 0.069LNR 9.562 0.248HNR 12.958 0.259CON 6.758 0.074NR 7.732 0.134Day 15NMN 9.445 0.103LNR 11.320 0.152HNR 16.232 0.052

[0198] Table 7: The P values of differences in plasma NAD+ content among NR; NMN, and LNR group Group One Group Two Day PNR <0.0001LNR Day 8NMN 0.0002NR <0.0001LNR Day 15NMN <0.0001

[0199] The changes in NAD+ content in the liver is shown in FIG. 2. The changes in NAD+ content in the liver on day 8 and day 15 were consistent with the changes in plasma, but the increase was greater and there were still differences in the degree of increase, HNR>LNR>NMN>NR.

[0200] Table 8: The Mean and standard error of liver NAD+ content in each group of miceGroup Day Average (nmol / g) SEMCON 89.768 7.629NR 237.292 5.023NMN Day 8 417.315 12.105LNR 522.487 1.716HNR 664.238 2.723CON 129.718 3.785NR 340.545 3.516NMN Day 15 392.530 4.952LNR 518.877 6.533HNR 821.878 26.615

[0201] Table 9: The P values of differences in liver NAD+ content among NR, NMN and LNR group Group One Group Two Day PNR <0.0001LNR Day 8NMN <0.0001NR <0.0001LNR Day 15NMN <0.0001

[0202] Example 4: Stability of Nicotinamide Riboside Proliposome Composition

[0203] The nicotinamide riboside proliposome composition prepared for the bioavailability investigation documented in Example 3, was also tested for stability at 25°C / 60% relative humidity (RH)). The proliposome composition was sealed in a black bag.

[0204] The parameters monitored were: Appearance (visual inspection - off-white, powder); Odour; Solubility (500 mg disperses as a colloidal solution in 250 ml water); Particle size (powder) by laser diffraction; Liposomal particle size (Z-average (d.nm)) by Multi-Angle Dynamic Light Scattering (100 mg powder dispersed in 100 ml water); and active ingredient (nicotinamide riboside chloride).

[0205] The results are shown in Table 10. Based on the results, and as shown in FIG. 3, it is expected that the nicotinamide riboside proliposome composition will have a 12-month shelf stability.

[0206] Table 10: Stability results for storage at 25°C / 60% RH.Time point0 1 2 3 6 (months)25°C / 60% 25°C / 60% 25°C / 60% 25°C / 60% 25°C / 60% Storage ConditionRH RH RH RH RHAppearance Complies Complies Complies Complies Complies Odour Complies Complies Complies Complies Complies Solubility Complies Complies Complies CompliesParticle size (powder) by laser diffractionMean (pm) 145.832 148.632 143.871 150.415 74.57 D10 (pm) 34.201 35.809 32.247 33.877 1.63 D50 (pm) 105.994 106.57 105.115 110.123 27.74 D90 (pm) 289.075 294.335 286.258 293.115 213.721 Liposomal particle size (Z-average (d.nm)) by Multi-Angle Dynamic Light Scattering ( 00 mg powder dispersed in 100 ml water)Z-Average (nm) 270.8 154 36.72 35.87 18.36 ACTIVE CONTENT ANALYSIS: NR = Nicotinamide Riboside ChlorideNR Content Upper600.00 600.00 600.00 600.00 600.00 limit (mg / g)NR Content535.10 540.50 529.50 520.20 492.40 (mg / g)NR Content450.00 450.00 450.00 450.00 450.00 Lower limit (mg / g)

[0207] Example 5: Small Scale Preparation of NAD+ Related Compound Proliposome Composition

[0208] A proliposome composition comprising nicotinamide mononucleotide (NMN) was prepared following the general procedure- The active ingredient was dispensed into a mixing vessel;- The lecithin:ethanol mixture was dispensed into the mixing vessel, wherein the lecithimethanol mixture (4:1 ratio) was prepared by mixing ethanol with lecithin with mixing at room temperature until the lecithin was solubilized;- Mixed thoroughly to coat the active ingredient with the lecith in : eth ano I mixture;- Dispensed the maltodextrin into the mixing vessel;- Mixed thoroughly until the powder is homogeneous.- Dispensed the colloidal silica (anhydrous) into the mixing vessel;- Mixed thoroughly until the powder is homogeneous.

[0209] The proliposome compositions included the ingredients as shown in Table 11.Table 11: Proliposome Composition - NMNIngredient gNMN 27.687lecithin:ethanol (4:1 ratio) 3.583Maltodextrin 17.979colloidal silica (anhydrous) 0.962

Claims

The invention claimed is:

1. A method of(1) increasing NAD+ in a subject;(2) mitigating age-related decreases in NAD+ in a subject;(3) mitigating a disease, condition, and / or symptom associated with aging in a subject;(4) delaying the onset of a disease, condition, and / or symptom associated with aging in a subject; (5) treating a disease, condition, and / or symptom associated with aging in a subject;(6) dietary management of a disease, condition, and / or symptom associated with aging in a subject; comprising administering to the subject a nicotinamide riboside proliposome composition,wherein the nicotinamide riboside proliposome comprises:(a) about 40% to about 70% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.

2. A method of(1) increasing NAD+ in a subject;(2) mitigating age-related decreases in NAD+ in a subject;(3) mitigating a disease, condition, and / or symptom associated with aging in a subject;(4) delaying the onset of a disease, condition, and / or symptom associated with aging in a subject; (5) treating a disease, condition, and / or symptom associated with aging in a subject;(6) dietary management of a disease, condition, and / or symptom associated with aging in a subject; comprising administering to the subject a proliposome composition,wherein the proliposome comprises:(a) about 40% to about 70% of a NAD+ related compound by weight based on the total weight of the composition;(b) about 3.3% to about 6.7% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45% dispersant by weight based on the total weight of the composition; and (d) about 1.4% to about 2.4% excipient by weight based on the total weight of the composition.

3. The method of claim 2, wherein the NDA+ related compound comprises one or more of nicotinamide riboside chloride, a water soluble salt of nicotinamide riboside, nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR).

4. The method of claim 3, wherein the NDA+ related compound comprises nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR.

5. The method of any one of claims 1 to 4, wherein the proliposome composition comprises no more than 2% organic solvent by weight based on the total weight of the composition.

6. The method of any one of claims 1 to 5, wherein the composition has a mean particle size of no more than about 400 m, no more than about 350 pm, or no more than about 300 pm.

7. The method of claim 6, wherein the composition has a mean particle size of no more than about 300 pm and wherein Dio is less than about pm, D50 is less than about 200 pm, and D90 is less than about 400 pm.

8. The method of any one of claims 1 to 7, wherein when 100 mg of the composition is mixed with 100 ml of water, the liposomal particle size (Z-average (d.nm)) is less than about 400, less than about 350, or less than about 300.

9. The method of any one of claims 1 to 8, wherein the method is a method of increasing NAD+ in a subject or mitigating age-related decreases in NAD+ in a subject, wherein the subject(a) is overweight or obese; and / or(b) has diabetes, hypertension, fatty liver, a cardiovascular disease, neurodegeneration, a muscular disease, and / or cancer.

10. The method of any one of claims 1 to 9, wherein the(a) the disease, condition, and / or symptom is linked to decreased NAD+; or(b) the disease, condition, and / or symptom is linked to decreased NAD+ and, wherein the disease, condition, and / or symptom is one or more of diabetes, being overweight, obesity.

11. The method of any one of claims 1 to 10, wherein the composition comprises(I)(a) about 47% to about 64% nicotinamide riboside chloride or NAD+ related compound by weight based on the total weight of the composition;(b) about 3.8% to about 6.2% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 30% to about 41% dispersant by weight based on the total weight of the composition; and(d) about 1.6% to about 2.2% excipient by weight based on the total weight of the composition;or(II)(a) about 52% to about 58% nicotinamide riboside chloride or NAD+ related compound by weight based on the total weight of the composition;(b) about 4.3% to about 5.6% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 34% to about 37% dispersant by weight based on the total weight of the composition; and(d) about 1.8% to about 2.0% excipient by weight based on the total weight of the composition;12. The method of any one of claims 1 to 11, wherein the composition comprises about 0.5% to about 2.0 % or about 0.5% to about 1.5% organic solvent by weight based on the total weight of the composition.

13. The method of any one of claims 1 to 12, where in wherein the lipid system comprises about 65% to about 85% or about 70% to about 80% phospholipid by weight based on the total weight of the lipid system; and wherein the phospholipid comprises(a) at least about 70% phosphatidylcholine (PC) by weight based on the total weight of the phospholipid; about 3.0% to about 5.0% lysophosphatidylcholine (LPC) by weight based on the total weight of the phospholipid; and(c) about 0.5% to about 0.8% phosphotidylethanolamine (PE) by weight based on the total weight of the phospholipid;(b) at least about 80% PC by weight based on the total weight of the phospholipid; about 3.4% to about 4.6% LPC by weight based on the total weight of the phospholipid; and about 0.55% to about 0.75% PE by weight based on the total weight of the phospholipid; or(c) at least about 90% PC by weight based on the total weight of the phospholipid; about 3.8% to about 4.2% LPC by weight based on the total weight of the phospholipid; and about 0.6% to about 0.7% PE by weight based on the total weight of the phospholipid.

14. The method of claim 13, wherein in (a) the phospholipid comprises at least about 70% to about 97% PC;in (b) the phospholipid comprises at least about 80% to about 97% PC; or in (c) the phospholipid comprises at least about 90% to about 97% PC.

15. The method of any one of claims 1 to 14, wherein the lipid system comprises or consists essentially of deoiled lecithin.

16. The method of any one of claims 1 to 15, wherein the deoiled lecithin is sunflower deoiled lecithin.

17. The method of any one of claims 1 to 16, wherein one or more of the following apply:(a) the dispersant is one or more of lactose, maltodextrin, mannitol, sorbitol, sucrose, trehalose, and xylitol;(b) the dispersant is maltodextrin;(c) the excipient is one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, and magnesium stearate;(d) the excipient is colloidal silica (anhydrous);(e) the organic solvent in ethanol; and(f) the dispersant is maltodextrin, the excipient is colloidal silica (anhydrous), and the organic solvent is ethanol.

18. A method of preparing a proliposome composition, comprising(a) preparing a first mixture of an organic solvent and a lipid system as herein described;(b) spraying the first mixture onto an active ingredient to form a second mixture, wherein the spraying is airless spraying;(c) adding to the second mixture a dispersant to form a third mixture; and(d) adding to the third mixture an excipient to form a final mixture.

19. The method of claim 18, wherein the method is carried out at about 20°C to about 25°C and / or wherein no additional liquid is added.

20. The method of claim 18 or claim 19, wherein the active ingredient comprises two or more active ingredients; the two or more the active ingredients are mixed prior to (b) to form a premix of active ingredients; and (b) is spraying the first mixture onto a premix of active ingredients to form the second mixture, wherein the spaying is airless spraying.

21. A method of preparing a proliposome composition, wherein the method comprises:(a) preparing a first mixture of an organic solvent and a lipid system as herein described;(a’) adding an active ingredient into a high shear mix;(b) spraying the first mixture onto the active ingredient to form a second mixture, wherein the spraying is airless spraying;(b’) mixing the second mixture in the high shear mixer;(c) adding to the second mixture a dispersant to form a third mixture;(c’) mixing the third mixture in the high shear mixer;(d) adding to the third mixture an excipient to form a final mixture; and(d’) mixing the final mixture in the high shear mixer;wherein(i) the method is carried out at about 20°C to about 25°C; and(ii) the mixing in each of (b’), (c’), and (d’) is no more than 10 minutes.

22. The method of claim 21, wherein the mixing of each of (b’), (c’), and (d’) is no more than 5 minutes.

23. The method of claim 21 or claim 22, wherein the active ingredient comprises two or more active ingredients;the two or more the active ingredients are added into the high shear mixture in (a’) and mixed to form a premix of active ingredients; and (b) is spraying the first mixture onto the premix of active ingredients to form the second mixture, wherein the spraying is airless spraying.

24. The proliposome composition obtained by the method of any one of claims 18 to 23, wherein the proliposome composition comprises(a) about 40% to about 70%, about 47% to about 64%, or about 52% to about 58%, of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.3% to about 6.7%, about 3.8% to about 6.2%, or about 4.3% to about 5.6%, of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45%, about 30% to about 41 %, or about 34% to about 37%, dispersant by weight based on the total weight of the composition;(d) about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition; and(e) no more than about 2%, about 0.5% to about 2%, no more than about 1.5%, or about 0.5% to about 1.5%, organic solvent based on the total weight of the composition.

25. The proliposome composition of claim 24, wherein the lipid system comprises about 65% to about 85% or about 70% to about 80% phospholipid or by weight based on the total weight of the lipid system; and wherein the phospholipid comprises(a) at least about 70% phosphatidylcholine (PC) by weight based on the total weight of the phospholipid; about 3.0% to about 5.0% lysophosphatidylcholine (LPC) by weight based on the total weight of the phospholipid; and(c) about 0.5% to about 0.8% phosphotidylethanolamine (PE) by weight based on the total weight of the phospholipid;(b) at least about 80% PC by weight based on the total weight of the phospholipid; about 3.4% to about 4.6% LPC by weight based on the total weight of the phospholipid; and about 0.55% to about 0.75% PE by weight based on the total weight of the phospholipid; or(c) at least about 90% PC by weight based on the total weight of the phospholipid; about 3.8% to about 4.2% LPC by weight based on the total weight of the phospholipid; and about 0.6% to about 0.7% PE by weight based on the total weight of the phospholipid.

26. The method of claim 25, wherein in (a) the phospholipid comprises at least about 70% to about 97% PC;in (b) the phospholipid comprises at least about 80% to about 97% PC; or in (c) the phospholipid comprises at least about 90% to about 97% PC.

27. The proliposome composition of any one of claims 24 to 26, wherein the lipid system comprises or consists essentially of deoiled lecithin.

28. The proliposome composition of any one of claims 24 to 27, wherein the deoiled lecithin is sunflower deoiled lecithin.

29. A proliposome composition, wherein the proliposome composition comprises(a) about 40% to about 70%, about 47% to about 64%, or about 52% to about 58%, of one or more active ingredients by weight based on the total weight of the composition;(b) about 3.3% to about 6.7%, about 3.8% to about 6.2%, or about 4.3% to about 5.6%, of a lipid system by weight based on the total weight of the composition, wherein the lipid systemcomprises about 50% to about 95% phospholipid by weight based on the total weight of the lipid system;(c) about 26% to about 45%, about 30% to about 41 %, or about 34% to about 37%, dispersant by weight based on the total weight of the composition;(d) about 1.4% to about 2.4%, about 1.6% to about 2.2%, or about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition; and(e) no more than about 2%, about 0.5% to about 2%, no more than about 1.5%, or about 0.5% to about 1.5%, organic solvent based on the total weight of the composition.

30. The method of any one if claims 18 to 23 or the proliposome composition of claim 24 to 29, wherein one or more of the following apply:(a) the dispersant is one or more of lactose, maltodextrin, mannitol, sorbitol, sucrose, trehalose, and xylitol;(b) the dispersant is maltodextrin;(c) the excipient is one or more of colloidal silica (anhydrous), corn starch, calcium carbonate, and magnesium stearate;(d) the excipient is colloidal silica (anhydrous);(e) the organic solvent in ethanol; and(f) the dispersant is maltodextrin, the excipient is colloidal silica (anhydrous), and the organic solvent is ethanol.

31. The method of any one if claims 18 to 23 and 30 or the proliposome composition of claim 24 to 30, wherein (a) the composition has a mean particle size of no more than about 400 pm, no more than about 350 pm, or no more than about 300 pm;(b) the composition has a mean particle size of no more than about 300 pm and Dio is less than about 100 pm, D50 is less than about 200 pm, and D90 is less than about 400 pm; and / or (c) when 100 mg of the composition is mixed with 100 ml of water, the liposomal particle size (Z- average (d.nm)) is less than 400 nm, less than about 350 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, or less than about 50 nm.

32. The method of any one if claims 18 to 23, 30, and 31 or the proliposome composition of claim 24 to 31, wherein the active ingredients is(a) one or more of a vitamin, a peptide, an antioxidant, a flavonoid, a plant extracts, and spermidine; (b) one or more of a nicotinamide riboside salt, nicotinamide mononucleotide (NMN), nicotinic acid mononucleotide (NaMN), and nicotinic acid riboside (NaR);(c) nicotinamide riboside chloride and one or more of NMN, NaMN, and NaR; or(d) nicotinamide riboside chloride.

33. A proliposome composition, wherein the proliposome composition comprises(a) about 52% to about 58% nicotinamide riboside chloride by weight based on the total weight of the composition;(b) about 4.3% to about 5.6% of a lipid system by weight based on the total weight of the composition, wherein the lipid system comprises about 70% to about 80% phospholipid by weight based on the total weight of the lipid system;(c) about 34% to about 37%, dispersant by weight based on the total weight of the composition, wherein the dispersant is maltodextrin;(d) about 1.8% to about 2.0%, excipient by weight based on the total weight of the composition, wherein the excipient is colloidal silica (anhydrous); and(e) about 0.5% to about 1.5%, organic solvent based on the total weight of the composition, wherein the organic solvent is ethanol;wherein(i) the phospholipid comprises about 90% to about 97% PC by weight based on the total weight of the phospholipid; about 3.8% to about 4.2% LPC by weight based on the total weight of the phospholipid; and about 0.6% to about 0.7% PE by weight based on the total weight of the phospholipid;(ii) the composition is the lipid system is substantially free of phosphatidic acid (PA) and / or phosphatidylinositol (PI); and(iii) wherein the composition has a mean particle size of no more than about 300 pm.

34. The proliposome composition of claim 33, wherein when 100 mg of the composition is mixed with 100 ml of water, the liposomal particle size (Z-average (d.nm)) is less than about 300 nm.

35. The method of claim 1, wherein the proliposome composition is the proliposome composition of claim 33 or claim 34.

36. The method or proliposome composition of any one of claims 1 to 35, wherein the proliposome composition is formulated for oral administration.

37. The method or proliposome composition of claim 36, wherein the formulation for oral administration comprises combining the proliposome composition with one or more formulating excipients.